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Nature uses precise spatio-temporal control to maintain proper cellular function. Being 
able to replicate this control is an important step in investigating proteins. The research presented 
here uses photo-labile “caging” groups and light to control protein function including signaling 
cascades, protein localization and dimerization. Cell signaling is an essential process that allows 
cells to respond to extracellular stimuli. Four kinases, ERK2, p38α, JNK1 and PAK1, were 
targeted to optochemically control signal transduction. ERK2, p38α, and JNK1 are MAP kinases 
that are implicated in cell proliferation, apoptosis, motility, and differentiation. PAK1 is a 
serine/threonine kinase that affects focal adhesion dynamic and action reorganization. 
Incorporation of a photocaged lysine into the ATP binding pocket of PAK1 allowed for optical 
control of PAK1 kinase activity and paxillin focal adhesions.  Ras GTPases are membrane bound 
molecular switches involved in various pathways that convert stimuli into a cellular response. 
Membrane localization of Ras GTPases is determined by the C-terminal CaaX domain. Within 
the CaaX domain, cysteine residues are modified by the addition of a farnesyl group and two 
palmitoyl groups. Ultimately, photochemical control of membrane localization by CaaX domain 
signaling was used to determine the kinetics of CaaX domain processing. Src family tyrosine 
kinases are involved in cell proliferation, cytoskeletal alterations, differentiation, survival, 
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 v 
adhesion, and migration and are localized to the membrane through the modification of a SH4 
domain with myristoylation and palmitoylation. Optochemical control of SH4 domain mediated 
membrane localization was not achieved. Finally, the dimerization of FKBP12 and FRB was 
photochemically controlled by the development of a photo-cleavable rapamycin dimer. 
Rapamycin heterodimerizes FKBP12 and FRB and has been exploited as a research tool in a 
wide array of cellular processes. Photochemical control of protein localization and dimerization 
allows for precise spatial and temporal control over these processes, which will lend to the 
development of useful biological tools. 
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1.0  UNNATURAL AMINO ACID MUTAGENESIS AND PHOTOCHEMICAL 
CONTROL 
1.1 UNNATURAL AMINO ACID MUTAGENESIS  
In order to control protein function, the methodology of unnatural amino acid mutagenesis can 
used with photocaged amino acids. Unnatural amino acid mutagenesis allows for the genetic 
incorporation of amino acid analogs into proteins that can introduce new function. These 
functions can include bioorthogonal reactive handles, IR or NMR probes, fluorescent side 
chains, heavy atom side chains for structure determination and photolabile side chain for 
optochemical control.1   
1.1.1 History of Unnatural Amino Acid Mutagenesis 
Biosynthetic incorporation of unnatural amino acids first occurred in 1989. This was achieved 
through the chemical mis-aminoacylation of suppressor yeast tRNAs. When this tRNA-UAA 
was combined with the other necessary components for translation from E. coli cells, 
incorporation of the unnatural amino acid (UAA) at the TAG amber stop codon was achieved in 
vitro.2 While it was an important milestone in the UAA incorporation field, there were 
limitations to this approach. The tRNA aminoacylation yield was only 45% and the incorporation 
efficiency was only 15-20%. The low yields of these reactions required large amounts of starting 
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materials in order to obtain relevant protein quantities. In 1995, Schultz, Dougherty, Lester and 
co-workers achieved the first incorporation of an UAA in cells through injection of the 
aminoacylated suppressor yeast tRNA and mRNA containing a TAG stop codon into Xenopus 
oocytes.3 This method was used to incorporate tyrosine and phenylalanine analogs at three 
specific positions within the nicotinic acetylcholine receptor to investigate their importance in 
ligand binding.  
Beginning in 2001, genetic incorporation of UAAs emerged. The Schultz lab adapted a 
tyrosyl-tRNA and tyrosyl-tRNA synthetase (TyrRS) pair from Methanococcus jannaschii for 
amber stop codon suppression in E. coli.4 The tRNA was mutated in order to reduce recognition 
by endogenous E. coli synthetases and the TyrRS was randomized at 5 essential amino acid-
recognition sites in close proximity to the Tyr OH group; a selection was performed to identify a 
synthetase that specifically recognized the UAA, o-methyl-L-tyrosine and charges the cognate 
suppressor tRNA. By transforming E. coli with DNA that encoded the suppressor tRNA, the 
mutant TyrRS, and the gene of interest, dihydrofolate reductase containing a TAG mutation, the 
biosynthetic machinery of E. coli produced dihydrofolate reductase with o-methyl-L-tyrosine 
incorporated. The M. jannaschii pair has been extensively used in E. coli.1,5 In each of these 
examples, a library of mutant TyrRSs were subjected to a selection for the specific recognition of 
o-nitrobenzyl-o-tyrosine and sulfotyrosine, respectively. 
Incorporation of UAAs in eukaryotes has also been achieved. The yeast genetic code has 
been expanded with a tyrosyl-tRNA/TyrlRS pair from E. coli,6 a pyrrolysyl-tRNA/PylRS from 
Methanosarcina barkeri,7 and a leucyl-tRNA/LeuRS from E. coli.8 The first example of 
expression of proteins with UAAs in mammalian cells was in 2002 using a suppressor tRNA 
from Bacillus stearothermophilus and a TyrlRS from E. coli to encode 2-iodo-L-tyrosine.9 A 
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Bacillus subtillis suppressor tRNA and trypotophanylRS have also been using to incorporate 5-
hydroxytryptophan, a fluorescent probe, into mammalian cells.10  
In 2008, the Methanosarcina mazei pyrrolysyl-tRNA synthetase and tRNA pair was used 
for unnatural amino acid mutagenesis.11 Pyrrolysine is the 22nd amino acid and is incorporated in 
response to a UAG codon in archaea by a dedicated tRNA and pyrrolysyl-tRNA synthetase 
(PylRS).12 This natural amber suppression system was adapted to several UAAs, in a similar way 
as the TyrRS and LeuRS enzymes were engineered previously. Initial UAAs that were encoded 
using mutant PylRS enzymes were Nε-benzyloxycarbonyl-L-lysine,11 krzyNε-acetyl-L-lysine,13 
and o-nitrobenzyl-oxycarbonyl-Nε-L-lysine.14,15  
In 2009, the Deiters and Chin labs used the M. bakeri PylRS/tRNA pair to incorporate a 
photocaged lysine (PCK, Figure 1).16 The PylRS was mutated at five positions and three rounds 
of positive and negative selection yielded a synthetase (PCKRS) with mutations (M241F, 
A267S, Y271C, and L274M) that specifically enabled incorporation of PCK.  
 
   
Figure 1: Structure of the photocaged lysine PCK.  
 
In order to successfully incorporate unnatural amino acids into mammalian cells, the 
suppressor tRNA, the corresponding aminoacyl tRNA synthetase (RS), the unnatural amino acid, 
and the DNA encoding the protein of interest containing the TAG mutation must all be present 
(Figure 2A). When added to the growth media of mammalian cells, the UAA will be transported 
into the cell. Plasmid DNA encoding the suppressor tRNA and the RS is transfected into cells 
HN O
O
O2N O
O
CO2HH2N
PCK 
 4 
and the endogenous cellular machinery expresses the tRNA and RS for incorporation and 
expression of the protein of interest. The RS, evolved for the UAA (shown in red), will 
specifically charge the suppressor tRNA (shown in blue) with the unnatural amino acid (shown 
in blue). The evolved RS is orthogonal to all endogenous tRNAs and the suppressor tRNA is 
orthogonal to all endogenous RSs. The acylated suppressor tRNA than delivers the UAA in 
response to the UAG codon that was introduced into the mRNA of the protein of interest, 
enabling site-specific incorporation into the growing polypeptide chain at the desired residue.  
 
Figure 2: A) Schematic of unnatural amino acid incorporation. This research was originally published in Journal of 
Biological Chemistry. Young, T.S and Schultz, P.G. Beyond the Canonical 20 Amino Acids: Expanding the Genetic 
Lexison. Journal of Biological Chemistry. 2010; 285:11039-11044. © the American Society for Biochemistry and 
Molecular Biology. B) Incorporation of PCK into a reporter plasmid. Adapted with permission from Gautier, A. et. 
al. 2010, 132. Copyright 2010 American Chemical Society. 
 
PCK incorporation was validated by using a reporter construct in human embryonic 
kidney (HEK293T) cells (Figure 2B) that only shows EGFP fluorescence after suppression of 
TAG codon. EGFP fluorescence is only observed in the presence of PCK, demonstrating a high 
specificity of the mutant synthetase for the UAA over any of the endogenous amino acids. These 
results were further confirmed by MS/MS analysis.  
– PCK 
+ 1mM  
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The field of unnatural amino acid mutagenesis is rapidly expanding. Most recently this 
has include the incorporation of UAAs into mouse tissue, C. elegans, and D. melanogaster.17-20 
 
1.2 PHOTOCHEMICAL CONTROL 
Nature has developed precise spatial and temporal control of biological processes on the 
unicellular and multicellular level. Processes such as DNA replication,21 cell signaling,22 
molecular transport,23 and protein biosynthesis24 depend on the location of proteins, DNA, and 
other biomolecules and the timing of their activity and interactions. In trying to elucidate the 
mechanisms of cellular processes, it is crucial to examine them with conditional activation that 
allows for spatiotemporal control comparable to that of the natural system.25,26 Light is a unique 
external regulatory element that can be used to control biological processes with high resolution. 
The simplicity and accuracy of timing, location, and amplitude associated with light exposure 
makes it an ideal non-invasive technique for use in biology.25,27-29  
1.2.1 Methods for Photochemical Control 
Photochemical control of proteins can be achieved through the application of multiple 
methodologies (Figure 3). These methodologies include optogenetic approaches such as the use 
of LOV domains, phytochromes/cryptochromes, and channelrhodopsins as well as the use of 
photoremovable protecting groups or  “caging groups”.30,31 Caging groups can be added to a 
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critical position within the protein (or to small molecule effectors) to render the molecule 
inactive until the group is removed through light exposure, typically UV light of ≥365nm. 
  
Figure 3: Schematic of methods for photochemical control of biological processes. Adapted with permission from 
Baker, A. S.; Deiters, A. ACS Chemical Biology 2014, 9, 1398. Copyright 2014 American Chemical Society. 
 
 
1.2.1.1 Optogenetic Approaches 
Optogenetic approaches include the use of photo-responsive proteins that are found in Nature. 
These include light-oxygen-voltage (LOV) sensitive domains, channelrhodopsins, phytochromes, 
and cryptochromes. These approaches have been used to control various cellular functions 
including transcription, DNA recombination, post-translational modifications, cytoskeleton 
dynamics, signaling, and localization (Table 1).  
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Table 1: Functions that have been controlled by LOV domains, phytochromes, and crytochromes. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Chemical Biology, Gautier, A.; Gauron, C.; Volovitch, M.; 
Bensimon, D.; Jullien, L.; Vriz, S., How to control proteins with light in living systems.  2014, 10 (7), 533-41, 
copyright 2014. 
 
 
The LOV domain is found in all kingdoms of life and was first discovered in plants. It is 
a photoreceptor kinase that uses a flavin mononucleotide to bind a conserved cysteine residue 
within the kinase. Photoexcitation of the LOV domain induces a structural change that allows for 
activation.32 The LOV domain has also been used to control the activity of dihydrofolate 
reductase, zinc finger transcription factors, GTPases, and tryptophan repressors.29-31 
One recent application of the LOV domain is the optical control of organelle transport.33 
This was first demonstrated with peroxisomes. A peroxisome-targeting domain fused with red 
fluorescent protein (RFP) and a LOV domain containing a caged peptide that binds ePDZb1 was 
designed along with a second fusion protein containing the ePDZb1, GFP, and kinesin (Figure 
4A). Kinesin is a motor protein that moves along microtubules. Expression of these proteins in 
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COS-7 cells showed localization of the PEX-LOV fusion protein to the center of the cell before 
light exposure presumably because the PEX-LOV protein was localized to peroxisome due to the 
peroxisome-targeting moiety. After a brief irradiation with blue light, the ePDZb1-binding 
peptide was exposed due to conformational change of the LOV domain (Figure 4A) and the 
peroxisome became bound to kinesin. This allowed for the transport of the peroxisomes to the 
outer edge of the cell (Figure 4B). Peroxisomes did not move before irradiation with blue light. 
This indicated that LOV domains are capable of temporal control of peroxisome localization 
within cells.  
 Furthermore, peroxisome transportation could be controlled spatially (Figure 4C). The 
colored rectangles were irradiated with blue light sequentially and the movement of the 
peroxisomes was analyzed (Figure 4D). After irradiation, the peroxisomes moved towards the 
outer edge of the cells, but only from the areas that were exposed to blue light. Peroxisomes in 
the non-irradiated areas did not move from their initial locations. This demonstrated the ability 
for the LOV domain in this system to be used to spatially control protein localization within 
cells.  
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Figure 4: A) Schematic of experimental design for peroxisome transport using a LOV domain. B) Cellular 
localization of peroxisomes before and after illumination with blue light. C) Spatial irradiation of cells with PEX-
LOV D) Movement of peroxisomes after spatial irradiation. Adapted by permission from Macmillan Publishers Ltd: 
Nature, van Bergeijk, P.; Adrian, M.; Hoogenraad, C. C.; Kapitein, L. C., Optogenetic control of organelle transport 
and positioning. 2015, 518 (7537), 111-4, copyright 2015.  
 
This experimental design proved to be modular, as the researchers were able to control 
the localization of recycled endosomes and mitochondria temporally and spatially. The ability to 
control protein localization within the cell with tight spatiotemporal control will lend to the study 
of how organelle function is affected by their position as well controlling cellular processes like 
movement and signaling.  
Channelrhodopsins contain a blue light-sensing chromophore that opens to form a pore 
upon exposure; this pore is then available for a flux of ions. The first channelrhodopsin was 
discovered in 2002 and was found to conduct multiple mono and divalent cations.34 Within three 
years, channelrhodopsins were introduced into neuronal cells to change the charge potential. This 
approach has been successful in the study of neuron function,35 and was featured as the Nature 
Methods method of the year in 2011.36 Since the discovery of channelrhodopsins, multiple 
A 
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modifications including codon optimization, amino acid mutations and trafficking mutations 
have been made.37 Along with these mutations, variations in the activation wavelength and 
kinetics have been introduced. Channelrhodopsins can now be activated with wavelengths from 
450 to 550 nm and can vary in the time of deactivation from seconds up to 30 minutes.  
Phytochromes (Phy) and cryptochromes (Cry) are proteins that undergo conformational 
changed through absorptions of a photon. This structural change allows for the binding of a 
phytochrome interaction factor (PIF) and a cryptochrome-interact basic-helix-loop-helix protein 
(CIB), respectively.30 This technology has been used to control transcription, Cre recombinase, 
histone acetylation, actin dynamics, signaling, and membrane localization.30,31 
One application of the Phy technology is shown in Figure 5.38 Upon irradiation with light 
of 650 nm, PIF and Phy interact (Figure 5A). Phy was localized to the membrane using a CaaX 
domain and YFP was fused to PIF (Figure 5B). When this system was expressed in mammalian 
cells, the membrane localization of YFP could be controlled by 650 nm irradiation (Figure 5C). 
Membrane localization was reversed when light with 750 nm was used and alternating light 
irradiations led to repeated localization of YFP fluorescence to the membrane and the cytoplasm.  
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Figure 5: A) Phy and PIF interaction triggered by 650 nm light. B) Schematic of YFP membrane localization using 
Phy and PIF domains. C) Fluorescence microscopy of YFP localization when cell was irradiated with 650 nm and 
750 nm light. Reprinted by permission from Macmillan Publishers Ltd: Nature, Levskaya, A.; Weiner, O. D.; Lim, 
W. A.; Voigt, C. A., Spatiotemporal control of cell signaling using a light-switchable protein interaction. 2009, 461 
(7266), 997-1001, copyright 2009.  
 
 Using this conditional membrane localization, kinase activity was controlled (Figure 6). 
The membrane bound Phy was used to optically recruit Tiam, a Rac activator, through a PIF 
fusion (Figure 6A). The activation of Rac was observed by the development of lamellipodia 
(Figure 6B).  
 
Figure 6: A) Schematic of membrane bound Phy and Tiam-PIF. B) Protrusion of mammalian cells through the 
activation of Rac by the membrane localization of Tiam. Tiam is localized to the membrane by the Phy-PIF 
interaction and subsequent activation of Rac is observed by the development of cellular lamellipodia. Reprinted by 
permission from Macmillan Publishers Ltd: Nature, Levskaya, A.; Weiner, O. D.; Lim, W. A.; Voigt, C. A., 
A 
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Spatiotemporal control of cell signalling using a light-switchable protein interaction. 2009, 461 (7266), 997-1001, 
copyright 2009. 
 
 Membrane localization has also been controlled with crytochrome domains (Figure 7). 
Here, the Cry domain was fused to a red fluorescent protein and its binding partner, CIB, was 
fused to a membrane localized green fluorescent protein (Figure 7A).39 Before stimulation with 
blue light, red fluorescence can be seen throughout the cell (Figure 7B). After stimulation, the 
red fluorescence is localized at the membrane through an induced interaction of Cry and CIB.  
 
Figure 7: A) Schematic of membrane localization using a Cry and CIB domain. B) Localization of red fluorescent 
protein only after stimulation with blue light. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Methods, Kennedy, M.; Hughes, R.; Peteya, L.; Schwartz, J.; Ehlers, M.; Tucker, C., Rapid blue-light-mediated 
induction of protein interactions in living cells.  2010, 7 (12), 973-U48, copyright 2010.  
 
 
Cryptochrome technology has also been applied to conditional transcriptional activation 
using light-inducible transcription effectors (LITE, Figure 8).40 A transcription activator-like 
effector (TALE), which recognizes a specific DNA sequence, is fused to a Cry domain and upon 
irradiation recruits a CIB-transcription factor fusion protein, activating the gene downstream 
(Figure 8A). This was demonstrated by designing a LITE for the Grm2 gene and following the 
mRNA and protein levels in response to illumination (Figure 8B, Figure 8C). Before light 
stimulation, only background levels of mRNA (Figure 8B) and protein (Figure 8C) were 
observed. However, after irradiation with 466 nm light, both were increased by 2.5- and 7-fold, 
respectively.  
A B 
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Figure 8: A) Schematic of light-inducible transcription effectors (LITE) B) mRNA expression changes and C) 
protein level changes of Grm2 in response to LITE. Reprinted by permission from Macmillan Publishers Ltd: 
Nature, Konermann, S.; Brigham, M. D.; Trevino, A. E.; Hsu, P. D.; Heidenreich, M.; Cong, L.; Platt, R. J.; Scott, 
D. A.; Church, G. M.; Zhang, F., Optical control of mammalian endogenous transcription and epigenetic states. 
2013, 500 (7463), 472-6, copyright 2013. 
 
While these methods have been used successfully to control a wide range of biological 
processes, they require fusions of the photoresponsive proteins and the protein of interest. This 
can be difficult to implement and may not be possible for all proteins.  
1.2.1.2 Photocaged Small-molecules 
For proteins that are activated or deactivated through a small molecule interaction, the small 
molecule can be modified with a caging group to provide photochemical control. Small 
molecules that have been popular targets are agonists of inducible gene expression systems such 
as ecdysone,41 IPTG,42 doxycycline,43 and toyocamycin.44 The small molecules act as 
transcriptional and translational modulators and are functional in bacterial and mammalian cells. 
There are also small molecule effectors that can work at the post-translational level of protein 
A 
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synthesis, e.g., photocaged rapamycin analogs.45,46 These will be described in detail in Chapter 5.
  
1.2.1.3 Photocaged Proteins 
Caged proteins can be generated in multiple ways, including non-specific modification of 
amino acid residues, protein synthesis, and unnatural amino acid incorporation.47,48 Protein 
ligation to form photocaged amino acids uses semisynthetic methods (Figure 9A).49 For example, 
Smad2 (shown in orange in Figure 9A) minus the last five amino acids fused with the Smad-
binding domain (SBD) of the Smad anchor for receptor activation (SARA) (shown in blue and 
gold)-maltose binding protein (MBP) was expressed in bacteria. The SBD-SARA-MBP fusion 
was necessary for increased stability of the Smad2. The last five amino acids with two 
phosphates, a carboxyfluorescein, and a quencher were synthetically prepared and the two parts 
were then ligated together to form the photocaged Smad2 complex.50 The presence of the C-
terminal caging group inhibited the homotrimerization of the SBD-SARA fusions. After 
irradiation, green fluorescence is present due to the removal of the quencher (Figure 9B) and 
homotrimerization can occur. A second caged Smad2 was designed without the phosphates on 
the peptide. When both of these were introduced into mammalian cells, there was very little 
fluorescence seen before irradiation (Figure 9B). After irradiation, fluorescence is seen and the 
localization of each Smad2 can be observed. The phosphorylated Smad2 was found in the 
cytoplasm and the nucleus, while the nonphosphorylated variants were found exclusively in the 
cytoplasm, supporting previous studies.  
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Figure 9: A) Generation of caged Smad2 through expressed protein ligation and decaging. B) Observed 
fluorescence of caged Smad2 complexes before and after UV irradiation and cellular localization. Hahn, M. E., 
Pellois, J. P., Vila-Perello, M. & Muir, T. W. Tunable photoactivation of a post-translationally modified signaling 
protein and its unmodified counterpart in live cells. Chembiochem 8, 2100-2105, doi:10.1002/cbic.200700404 
(2007). Copyright 2007.  
 
An example of generating photocaged amino acids using chemical modification was 
published by Ghosh and coworkers.51 They applied α -bromo-(2-nitrophenyl)acetic acid to 
covalently modify a serine or cysteine side chain of cofilin (Figure 10). Cofilin is inactivated 
through a phosphorylation target of by LIM-kinase. The modification of S3 with α -bromo-(2-
nitrophenyl)acetic acid generates a photocaged cofilin that is recognized as a phosphorylated 
serine and cofilin remained inactive. Upon irradiation and caging group removal, serine is 
A 
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immediately phosphorylated and inactivated again. Site directed mutagenesis of S3 to cysteine 
produces a constitutively active cofilin that can also be caged. Upon treatment with α-bromo-(2-
nitrophenyl)acetic acid a caged cofilin is generated and with irradiation, a constitutively active 
cofilin is generated as the cysteine side chain cannot be phosphorylated to inactivate cofilin. This 
was used to determine that cofilin assists in the formation of actin polymers and also contributes 
to the directionality of cell movement.52 Before the use of photocaging to conditionally control 
cofilin, these questions were unanswered.  
 
 
Figure 10: Schematic of cofilin deactivation by phosphorylation and the various forms of cofilin that were 
generated by Ghosh and coworkers. Adapted with permission from Lee, H. M., Larson, D. R. & Lawrence, D. S. 
Illuminating the chemistry of life: design, synthesis, and applications of "caged" and related photoresponsive 
compounds. ACS Chem Biol 4, 409-427, doi:10.1021/cb900036s (2009). Copyright 2009 American Chemical 
Society. 
 
 
 
 
1.2.1.4 Photocaged Unnatural Amino Acids 
Unnatural amino acids for the photochemical control of protein function include o-nitrobenzyl 
derivatives of tyrosine,53,54 serine,55 cysteine,19,56-58 and lysine (PCK).7,14,16  
The caging of proteins in cells through UAA incorporation has several distinct advantages over 
other optogenetic approaches. First, the caging group is very small (150-250 Da) and induces 
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little to no perturbation to the overall protein structure, enabling precise optical control of distinct 
functions. Second, the positioning of the caged amino acid can be determined based on protein 
structure or protein mechanistic information, thus obviating the need for extensive rounds of 
trial-and-error and protein engineering. However, the location of the caged amino acid must be at 
a position within the protein that will not interrupt caged protein expression and folding. Third, 
light exposure removes the caging group and generates the native, wild type protein. Irradiation 
with >360 nm light has been shown to cause no or minimal damage to biological systems. 59,60 
The incorporation of PCK was used to photochemically control protein localization using 
a nuclear localization signal (NLS), Figure 11A.16 Within the NLS, a key lysine residue, that 
shows a decrease in nuclear localization when mutated to an aparagine,61 was mutated to a TAG 
codon. An NLS-PCK-GFP fusion is expressed, showing fluorescence distributed throughout the 
cell, indicating inactivity of the caged NLS (Figure 11B). After UV irradiation, the native lysine 
is restored due to decaging and the NLS becomes fully active, as seen by the  complete nuclear 
localization of GFP (Figure 11B). Because the starting point of translocation is known due to the 
timepoint of irradiation, the kinetics of nuclear import can be determined (Figure 11C). It was 
found that translocation from the cytoplasm to the nucleus had a half-time of ~20 seconds. 
Kinetic analysis of this specific NLS had not been performed until this investigation. Other 
analyses of bipartite NLSs have been performed when they are fused with various proteins of 
interest.62 These studies were done by injecting cells with the NLS-tagged proteins and the half-
time appears to be much longer compared to when the caged NLS was used.  
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Figure 11: A) Nuclear localization sequence and position of the TAG mutation for incorporation of PCK. B) 
Cellular phenotype of wtNLS, NLS-A (alanine mutant) and NLS-PCK (denoted by * in figure) before and after 
irradiation. C) Time course of NLS-PCK translocation after UV irradiation. Adapted with permission from Gautier, 
A.; Nguyen, D.; Lusic, H.; An, W.; Deiters, A.; Chin, J. J Am Chem Soc 2010, 132, 4086. Copyright 2010 American 
Chemical Society. 
 
The site-specific incorporation of PCK and related caged amino acids enables the 
expression of photocaged proteins directly in mammalian cells.54,58,63-65 This allows for tight 
spatiotemporal control of that protein and the cellular process to which it contributes. The work 
presented in this dissertation will use PCK and the above described unnatural amino acid 
mutagenesis to explore kinase signaling, membrane localization, and other cellular processes.  
A B C 
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2.0  OPTICAL CONTROL OF SIGNAL TRANSDUCTION 
Protein phosphorylation is an important post-translational modification that occurs on 
approximately 30% of cellular proteins.66 Phosphorylation is catalyzed by kinases through 
transfer of the γ-phosphate from ATP or GTP to their protein target. This modification generates 
a conformational change that alters function or protein-protein interactions. Recognizing that this 
was an important aspect of cellular signaling, in 2002, the human kinome project was generate.67 
Manning and coworkers used sequence comparisons to evaluate the genome and found 518 
potential kinases. This revealed the vast number of protein kinases throughout mammalian cells 
that are responsible for a vast array of cellular responses including, proliferation, differentiation, 
metabolism, cell structure and apoptosis.67 
Conditional control of kinases has been an important research topic. Activation of kinases 
with light instead of traditional approaches such as genetic knockouts or small molecule 
inhibitors allows for precise temporal control of activation and limits the ability of the cell to 
adapt to the stimulation.68-70 This unambiguous spatially and temporally controlled activation of 
kinases allows for the study of downstream targets, the kinetics of phosphorylation, feedback 
loops, and the resulting cellular response. Controlling kinases with light also allows for sub 
network control of the signaling pathways. Kinases throughout the pathway can be 
optochemically controlled to allow for insights into the function and feedback of each kinase.  
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 Wu and coworkers developed a photoactivatable Rac1 using the LOV domain (Figure 
12A).71 Before irradiation, Rac1 is unable to bind with its downstream effector PAK1. The 
photoactivatable Rac1 was expressed in mammalian cells and used to investigate the motility of 
cells upon activation (Figure 12B). Upon irradiation, indicated by the yellow dot in Figure 12B, 
the closest cellular edge expanded while the opposite edge retracted. The red area, showing the 
new leading edge, and the purple area, which shows the original opposite edge, indicates that 
within 5 minutes of irradiation Rac1 is functional. Conversely, when the dominant negative 
variant of Rac1 is used with the photoactivatable LOV domain, the opposite cellular polarity is 
seen. Using the LOV domain allows for the reversible activation of Rac1, which can be used to 
study the motility of cells. The photoactivatable Rac1 was used to determine that Rac1 activation 
alone was adequate to induce cell polarity and movement, as well as to elucidate that PAK1 
plays a role in aiding the development of protrusions. When PAK1 was inhibited with an 
inhibitory domain peptide, no membrane protrusions were observed upon activation of Rac1 
with light. In contrast, myosin does not contribute to Rac1 induced protrusions, but it was found 
that cell motility directionality is diminished when myosin is inhibited. Finally, the use of a 
photoactivatable Rac1 was used to determine that RhoA is inhibited upon activation of Rac1. 
This had been disputed in the literature previously and the ability to spatially and temporally 
induce Rac1 activity allowed for the observation, through a RhoA biosensor, that Rac1 inhibits 
RhoA.  
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Figure 12: A) Schematic of optochemical control of Rac1 using LOV domain. B) Motility of mammalian cell 
expressing the LOV-Rac1 fusion protein. Cells were irradiation at the position indicated in yellow. Cells protrusion 
is indicated by red and cell retraction is indicated by purple. The first box shows the motility of a cell expressing the 
photoactivatable constitutively active Rac1, and the second box shows the motility of a cell expressing the 
photoactivatable dominant negative Rac1. Reprinted by permission from Macmillan Publishers Ltd: Nature Wu, Y. 
I.; Frey, D.; Lungu, O. I.; Jaehrig, A.; Schlichting, I.; Kuhlman, B.; Hahn, K. M. Nature 2009, 461, 104, copyright 
2009.  
 
 
In 2011, Gautier and coworkers targeted the ATP binding pocket using PCK to control 
MEK1 activity.65 PCK was genetically incorporated into position 97. This blocks binding of 
ATP until UV irradiation, decaging and restoration of the native lysine. Figure 13A shows that 
expression of constitutive active MEK1, denoted as A in lane 2, in mammalian cells 
phosphorylates ERK1/2. The caged MEK1, denoted as C in lanes 7-10, shows no ERK1/2 
phosphorylation in the absence of UV irradiation. This is because PCK is encoded at position 97 
and ATP cannot bind to the kinase. Upon irradiation and a short reaction time, ERK1/2 
phosphorylation can be seen. The amount of ERK1/2 phosphorylation increases with increasing 
reaction time as expected. Furthermore, caged MEK1 can be expressed in mammalian cells and 
ERK1/2 localization can be observed in real time (Figure 13B). MEK1 phosphorylates ERK1/2 
and induces translocation to the nucleus where it continues the signaling cascade through 
phosphorylation of transcription factors: c-myc, CREB, c-Jun, and ets. These transcription 
factors play a role in cell proliferation, apoptosis and cell cycle.72-74 The translocation of ERK1/2 
upon phosphorylation by MEK1 can be utilized to determine MEK1 kinase activity. In cells 
expressing EGFP-ERK2 and caged MEK1, EGFP fluorescence can be seen in the cytoplasm 
A B 
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before UV irradiation. This is due to the inactivity of MEK1 and lack of phosphorylation on 
ERK2. After irradiation, translocation of EGFP-ERK2 can be seen. Translocation occurs because 
caged MEK1 is decaged, which restores the native lysine at position 97 and the function of 
MEK1. MEK1 then phosphorylates EGFP-ERK2 and EGFP-ERK2 is quickly translocated to the 
nucleus. Epidermal growth factor (EFP) stimulates the receptor to begin the signaling cascade 
(Figure 13) and was shown to induce translocation within 4.5 minutes.  Stimulation with EGF 
also results in the eventual export of ERK2 from the nucleus through the dephosphorylation of 
ERK2 by MAPK phosphatases (MKP in Figure 13B). It was hypothesized that this 
dephosphorylation and export from the nucleus is a negative feedback loop that inactivates the 
signaling pathway. Nature uses negative feedback mechanisms to terminate signaling to avoid 
over activation of signaling pathways.75 Within 10 minutes of UV irradiation, the nuclear to 
cytoplasmic ratio of EGFP-ERK2 was found to be 4-fold higher. Light-activation of MEK1 
induced translocation within 1.5 minutes, thus yielding a quicker response. This is due to the 
immediate activation of MEK1, unlike activation with EGF, which must be transduced from the 
receptor. However, in contrast to EGFP activation, photoactivation of MEK shows a steady-state 
of nuclear localization of EGFP-ERK2 over time. This leads to the conclusion that the negative 
feedback loop inactivates a kinase upstream of MEK1 in the pathway and not MEK1. This is in 
agreement with previous research that determined negative feedback loops using tradition 
genetic approaches such as siRNA knockdown and small molecule inhibitors. Mammalian cells 
were stimulated with platelet-derived growth factor (PDGF), which initiates signaling through 
the phosphoinositide 3-kinase pathway and the ERK pathway, and using various combinations of 
knockdown and small molecular inhibitors, the phosphorylation levels of ERK1/2 and MEK 
were investigated. Through this work, it was determined that ERK-dependent negative feedback 
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loop mediates signaling downstream of Ras. Although negative feedback loops were determined 
using traditional genetic approached, an immense amount of data was required to validate their 
signaling pathway model.76 The kinetics of ERK2 phosphorylation had previously been 
investigated in vitro and a sigmoidal curve that was found when data were plotted was produced 
by the distributive, and not processive, phosphorylation of ERK2 at dual-phosphorylation sites 
by MEK1. This means that each phosphorylation site requires a separate kinase-substrate binding 
occurrence. It was hypothesized that the rate of import of ERK2 into the nucleus is determined 
by the MEK1 phosphorylation of ERK2. This was confirmed using photoactivatable MEK1 as 
the same sigmoidal kinetic graphs were observed for translocation of EGFP-ERK2 to the nucleus 
after irradiation and activation of MEK1. The determination of kinetics and the investigation of 
the negative feedback loop were possible because of the highly specific activation of MEK1. 
Light activation adds a precise level of control with minimal disruption compared to other 
techniques such as gene silencing or small molecule inhibition. Additionally, gene silencing and 
small molecule inhibition of kinases turn off function and have a slower reaction time in 
comparison to optochemical techniques, which turn on function as well as have a quicker 
initiation time. Being able to activate a signaling pathway at any point other than the cell 
membrane allows for investigation of temporal regulation of that pathway. Moreover, the 
approach of blocking the ATP binding site with PCK was proposed as a general approach to the 
optochemical control of kinases.  
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Figure 13: A) Phosphorylation of ERK2 by photocaged MEK1. MEK1-ΔN-A is a constitutively active variant of 
MEK1. Other forms used are identified as: D for dominant negative, and C for caged. IB denotes immunoblotting of 
specific proteins. B) Schematic and fluorescent images of EGFP-ERK2 nuclear import upon phosphorylation by 
MEK1 after UV irradiation. This is an unofficial adaptation of an article that appeared in an ACS publication. ACS 
has not endorsed the content of this adaptation or the context of its use. Gautier, A.; Deiters, A.; Chin, J. W. J Am 
Chem Soc 2011, 133, 2124. 
 
 
 Also in 2011, two rapamycin analogs were used to control a small GTPase and a kinase, 
respectively.45,46 Both of these examples are explained in Chapter 5.0 in detail. While conditional 
control of signal transduction proteins was successful using rapamycin analogs, they required 
fusion proteins, which could possibly interfere with protein function as well as a small molecule, 
which limits spatial control. Additional approaches for optochemically controlling kinases have 
been developed using the light sensitive protein domains described in Chapter 1.0 38,77 The use of 
a photocaged amino acid, specifically PCK, in the ATP binding pocket eliminates these limits. 
Using this approach, the research below will describe three different potential targets within the 
signaling pathway for optochemical control of signal transduction.    
A 
B 
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2.1 OPTICAL CONTROL OF CDC42 AND RHOA ACTIVITY 
2.1.1 Introduction 
The first proteins that were targeted for optochemical control of signal transduction were cdc42 
and RhoA. These are small molecular switches that cycle between GTP and GDP- bound states 
towards the beginning of the signaling cascade.78 Binding of GTP induces a conformational 
change, that allows binding and activation of effector proteins.79 cdc42 and RhoA have been 
implicated in the regulation of the cytoskeleton, transcription factors, cell-cycle progression, cell-
cell contact and cell transformation.78 Previous approaches to optochemically control cdc42 and 
RhoA have focused on their activation by Rac171 or have used a fused light-sensitive domain.38 It 
was hypothesized that RhoA and cdc42 could be directly controlled through the installation of 
PCK in the GTP binding pocket and this precise spatio-temporal control could be used to further 
investigate the feedback loops between GTPases and Rac1.71,80.  
2.1.2 Caged cdc42 and RhoA 
Plasmids expressing constitutively active and kinase dead RhoA (Q63L and T19N, respectively) 
and cdc42 (Q61L and T17N, respectively) were purchased from Addgene (plasmids #15900, 
#15901, #15906, and #15907). Site-directed mutagenesis was performed on the pRK5myc-
GTPase plasmid to introduce a TAG mutation at K16 of cdc42 and K18 of RhoA. These lysine 
residues are conserved in Rho, Rac, cdc42 and Ras isoforms and are located in the phosphate-
binding loop of the ATP binding pocket in each protein (Figure 14).81 The main chain and side 
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chain of this conserved lysine residue participate in hydrogen bonding with the phosphate group 
of the GTP substrate.  
 
Figure 14: Crystal structures of A) RhoA and B) cdc42. K18 of RhoA and K16 of cdc42 are highlighted in red. An 
ATP analog in the RhoA structure and ADP in the cdc42 structure are highlight in yellow. PDB structures 1A2B 
(RhoA) and 2NGR (cdc42).  
 
 HEK293T cells were transfected with the plasmid expressing PCKRS and PylT82 and 
pRK5myc-caRhoA K18TAG or pRK5myc-cacdc42 K16TAG in the presence of 1 mM of PCK. 
Twenty-four hours post-transfection, cells were lysed and analyzed for caged protein expression 
by Western blot using an anti-myc-tag antibody (Figure 15). Expression of the constitutively 
active and kinase dead mutant was detected, however no caged protein was detected for RhoA or 
cdc42 in the presence of PCK. Different parameters, such as PCK concentration, amount of 
DNA, transfection time, and lysis conditions, were explored but caged protein was not detected.  
   
Figure 15: Western blots of RhoA and cdc42 variants. “ca” designates the constitutively active variants and “dn” 
designates the enzymatically inactive variants.  
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2.1.3 Experimental 
Site-directed Mutagenesis. pRK5-myc-RhoA-Q63L and pRK5-myc-cdc42Q63L were mutated 
to contain K18TAG and K16TAG using the QuikChange Lightening protocol (Agilent). Primers 
were QC_RhoAK18TAG_Forw (5’-GATGGAGCCTGTGGATAGACATGCTTGCTC ATA) 
and QC_RhoAK18TAG_Rev (5’-TATGAGCAAGCATGTCTATCCACAGGCTCCATC) for 
mutation of RhoA. For mutation of cdc42, primers were QC_cdc42K16TAG_Forw (5’-GAT 
GGTGCTGTTGGTTAGAACTGTCTCCTGATA) and QC_cdc42K16TAG_Rev (5’-TATCAG 
GAGACAGTTCTAACCAACAGCACCATC) Annealing temperature was 60 ˚C and extension 
time was 4 minutes.  
 Western Blotting of Caged GTPases. HEK293T cells were maintained as described in 
Section 6.5 and split the day before transfection as described in Section 6.6. Transfection was 
performed with 1 µg of pRK5-myc-caGTPase TAG and 1 µg of pPCKRS-PylT or 2 µg of 
pRK5-myc-caGTPase or 2 µg of pRK5-myc-kdGTPase. Cells were incubated overnight at 37 
˚C/5% CO2. The next day cells were washed with 1 mL of PBS and lysed with 500 µL of 
Mammalian Protein Extraction Buffer (GE Healthcare). Cells were shaken on ice of 10 minutes 
and lysates were centrifuged for 10 minutes at maximum speed (15,000 rpm/21,130 × g). 
Western blot was performed as described in Section 6.9 with mouse anti-myc and mouse anti-
GAPDH antibodies (Santa Cruz) at a 1:1000 dilution. Secondary antibody was goat anti-mouse-
HRP (Santa Cruz) diluted 1:1000 in TBST. Detection method used for the cdc42 Western blot 
was colorimetric. Colorimetric detection was performed by mixing 120 µL of 0.3% hydrogen 
peroxide with 4 mg of 4-chloro-1naphthol (4CN) in 20 mL of TBS. This solution was added to 
the membrane and allowed to develop for 15 minutes. Images were taken with a scanner. RhoA 
Western blots were detected with chemifluorescent ECL 2 Western Blotting Substrate (Thermo 
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Scientific) on a Typhoon Phosphorimager using 457 nm excitation and 520/40 nm emission 
settings.  
 Optimization of Caged GTPase Expression. In an effort to express caged GTPases, 
multiple parameters were adjusted. The amount of DNA used for transfection ranged from 2 µg 
to 4 µg total. Lipofectamine 2000 and branched polyethylenimine (PEI) transfection reagents 
were used. During transfection, DNA and Lipofectamine 2000 were incubated with the cells for 
4 hours before media was changed and cells were incubated for 18-24 hours for protein 
expression. Branched PEI and DNA transfection mixtures were incubated on cells for 18-24 
hours. The concentration of PCK was also varied from 1 mM to 2 mM without successful 
incorporation. The Mammalian Protein Extraction Buffer (GE) as well as homemade PAK1 lysis 
buffer was used to lyse the cells before Western blotting. Caged GTPases were not detected by 
Western blot with any of the above optimizations.  
2.2 OPTICAL CONTROL OF PAK1 ACTIVITY 
2.2.1 Introduction 
The PAK (p21-activated kinases) protein family represents a group of serine/threonine kinases 
that are regulated by small GTPases, including CDC42 and Rac1 and are part of multiple signal 
pathways, including the ERK pathway (Figure 16). There are six members of the PAK family. 
PAK1 through 3 exhibit a higher level of homology than the recently discovered PAK4 through 
6. PAK1 specifically has a complex structure consisting an N-terminal regulatory domain, five 
SH3-binding domains, a CDC42 and Rac interaction binding domain, a p21-binding domain, an 
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autoinhibitory domain, and a C-terminal catalytic domain.83 Binding of PAKs to CDC42 or Rac1 
leads to conformational changes as well as the ability for PAKs to autophosphorylate. 
Autophosphorylation activates the kinase function of PAKs and induces conformational changes 
that expose the SH3 binding domain.84  
 
Figure 16: Signaling pathway including PAK1. Adapted from http://www.sabiosciences.com/pathway.php?sn= 
ERK_Signaling 
 
Downstream targets of PAK1 include paxillin85 and cofilin86 which affect focal adhesion 
turnover and actin polymerization, respectively.  It was further found that PAKs, PAK1 in 
particular, are critical for cell migration and establishing the spatiotemporal relationship between 
actin organization, myosin phosphorylation and focal adhesion dynamics.85,87 PAK1 has kinase-
dependent and kinase-independent functions, which have long been debated in the literature.83 
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pathway. This precise control of PAK1 could be used in the determination of the negative 
feedback loop in the ERK2 pathway that was discussed above.65,88,89 The hypothesis that Raf-1 is 
the target of the negative feedback loop can be tested using the photocaged PAK1.  
2.2.2 Caged PAK1 
In order to control PAK1 activity with light, constitutively activate PAK1 was mutated to have 
PCK incorporated at K299 (Figure 17). K299 has been shown to undergo an ionic interaction 
with glutamate 315 that stabilizes the α- and β-phosphates of ATP and contributes to the γ-
phospho-transfer.90  
 
Figure 17: Crystal structure of PAK1 with K299 highlighted in red, E315 highlighted in orange and ATP 
highlighted in yellow. Interactions are shown in dashed black lines. PDB structure 3Q53.  
 
 Plasmids expressing the constitutive active, denoted as “ca,” and inactive, denoted as 
“kd” for kinase dead, PAK1 containing myc tags were obtained from Addgene (plasmids: 
#12208 and #12210). In these plasmids, T423 was mutated to glutamate to induce constitutive 
activity and K299 was mutated to arginine to generate a catalytically inactive kinase. Mutation of 
K299 to TAG in the plasmid expression the caPAK1 yielded the plasmid pCMV6-myc-caPAK1 
K299TAG that could be used for expression of caged caPAK1 when transfected into mammalian 
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cells with the plasmid expressing the PCKRS and pylT. The wildtype PAK1 was also mutated to 
allow for incorporation of PCK. Figure 18 shows that, gratifyingly, when PCK was added to the 
media, caged caPAK1 was expressed and detected by Western blotting with an anti-myc 
antibody (lanes 3, 5, 9, and 11). As expected, expression levels are lower than those of non-
caged PAK1 (lanes 1, 2, 7, and 8).  
  
Figure 18: Western blot of PAK1 variants.  
 
Once expression of caged PAK1 was confirmed an activity assay was performed using 
myelin basic protein (MBP) as a phosphorylation target for PAK1.84,91 MBP is a generic target 
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K299 is restored and PAK1 becomes active, phosphorylating MBP (lane 9). When the wildtype 
caged variant of PAK1 is decaged (lane 11), only a minor band can be seen for MBP 
phosphorylation due to the reduced activity compared to the “ca” enzyme. In summary, the in 
vitro activity assay results in Figure 19 show that PAK1 activity can be optically controlled using 
PCK.  
  
Figure 19: In vitro kinase activity assay of PAK1 variants.  
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Figure 20: Time-lapse TIRF microscopy of a HeLa cells expressing caged ca PAK1 and GFP-Paxillin. The cell was 
irradiated with a DAPI filter at time 00. Arrows indicate focal adhesions that retract upon UV irradiation and 
activation of PAK1. Data was generated by Shoeb Ahmed of the Haugh Lab (North Carolina State University). 
 
2.2.3 Experimental  
All expression constructs were previously generated by Hank Chou in the Deiters lab. 
Western Blotting of Caged PAK1. HEK293T cells were maintained as described in 
Section 6.5 and split the day before transfection as described in Section 6.6. Transfection was 
performed with 1 µg of pCMV6-myc-caPAK1 K299TAG and 1 µg of pPCKRS-PylT or 2 µg of 
pCMV6-myc-caPAK or 2 µg of pCMV6-myc-kdPAK1 using the LPEI transfection protocol 
found in Section 00. Cells were incubated overnight at 37 ˚C/5% CO2. The next day cells were 
washed with 1 mL of PBS and lysed with 250 µL of PAK1 lysis buffer (2.5 mL 10% Triton X-
100, 1.25 mL 1 M Tris-HCl pH 7.4, and 1.67 mL 3 M sodium chloride filled to 50 mL with 
MilliQ water). Cells were shook on ice of 20 minutes and lysates were centrifuged to 20 minutes 
at 15,000 rpm. Western blot was performed as described in Section 6.9 with mouse anti-myc and 
mouse anti-GAPDH antibodies (Santa Cruz) at a 1:1000 dilution. Secondary antibody was goat 
anti-mouse-HRP (Santa Cruz) diluted 1:1000 in TBST. Colorimetric detection was performed by 
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mixing 120 µL of 0.3% hydrogen peroxide with 4 mg of 4-chloro-1naphthol (4CN) in 20 mL of 
TBS. This solution was added to the membrane and allowed to develop for 15 minutes. Images 
were taken with a scanner. 
Immunoprecipitation of PAK1. Lysate (200 µL) was mixed in a tube with 2 µg of anti-
myc antibody (Santa Cruz) and 30 µL of Protein A-Sepharose beads (Sigma). These were 
incubated overnight at 4 ˚C with shaking. The next day beads were centrifuged for 30 seconds at 
500 rpm/23 × g, the supernatant was decanted, beads were washed with 400 mL of wash solution 
A (20 mM Tris-HCl, pH 7.4 and 500 mM sodium chloride), and centrifuged again. This process 
was repeated twice with wash solution A and twice with was solution B (20 mM Tris-HCl, pH 
8.0 and 10 mM magnesium chloride). Beads were resuspended in 30 µL of kinase buffer (5X 
kinase buffer: 100 mM Tris-HCl, pH 7.4, 5 mM DTT, 50 mM magnesium chloride, 5 mM 
EDTA, 20 mM manganese chloride).  
Kinase assay. Each 20 µL kinase reaction contained 5 µL of the indicated PAK1-bead 
solution, 10 µg of myelin basic protein (Sigma Aldrich), 50 µM ATP, 10 µCi γ-32P-ATP in 1X 
kinase buffer. Reactions were incubated at 30 ˚C for 30 minutes, 5 µL of 4X SDS-PAGE loading 
dye was added to each sample and they were boiled for 5 minutes. Samples were separated on a 
15% SDS-PAGE gel. The gel was exposed to a phosphor storage screen overnight and scanned 
using a Typhoon Phosphorimager (GE Healthcare).  
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2.3 OPTICAL CONTROL OF MAPK KINASE ACTIVITY 
2.3.1 Introduction 
Multiple stimuli initiate ERK2, p38α, and JNK1 signaling cascades, however, the MAPKs are 
towards the end of the signaling cascade and typical translocate to the nucleus for terminal 
function.73,89 MAPK kinases have been implicated in a wide range of cellular processes including 
proliferation, migration, apoptosis, motility, structural support and differentiation. Furthermore, 
MAPK kinases have been associated with diseases such as Alzheimer’s disease, Parkinson’s 
disease, Lou Gehrig’s disease and cancer.73 It has been shown that crosstalk between the 
pathways of ERK2, p38α, and JNK1 is significant, however there are some upstream effectors 
that have been shown to be MAPK specific.89 The use of PCK to optically control MAPK kinase 
activity was hypothesized to allow for elucidation of co-regulatory signals and determination of 
crosstalk between MAPK signaling pathways. The ability to test this hypothesis is facilitated by 
specific activation of the kinase in question. Global activation through receptor stimulation 
causes reaction by all members of the pathway, which can create data that is difficult to interpret.   
2.3.2 Caged ERK2, p38α, and JNK1 
In order to optochemically control MAPK kinase activity, plasmids expressing wildtype ERK2, 
p38α, and MKK7-JNK1 were purchased from Addgene (plasmids #8974, #20351 and #19726). 
Three mutations are necessary to generate the constitutively active ERK2: L73P, S151D, and 
D319N.93 A constitutively active p38α variant requires two mutations, D176A and F372S, in 
combination with an MKK6 fusion (Addgene plasmid #13518), its upstream MAPKK.94 Site 
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directed mutagenesis was used to introduce a TAG mutation a K52, K53 and K55 of ERK2, 
p38α, and JNK1, respectively. This conserved lysine is located in the ATP binding pocket of all 
three MAPK kinases and plays a crucial role in positioning the triphosphate in the binding 
pocket for catalysis (Figure 21).95   
 
Figure 21: Crystal structures of A) ERK2, B) JNK1, and C) p38α. K52, K55, and K53, respectively are highlighted 
in red and point in to the ATP binding site. ADP is highlighted in yellow in the ERK2 structure. PDB structures 
4GVA (ERK2), 3O17 (JNK1), and 1R39 (p38α).  
 
Unfortunately, L74 was mutated to TAG instead of L73 in ERK2 and the incorrect lysine 
was mutated within JNK1 and p38α for incorporation of PCK. In JNK1, K55 should have been 
mutated to TAG, K56 was mutated to TAG and in p38α, K53 should have been mutated to TAG, 
A B 
C 
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but K54 was mutated to TAG due to incorrect primer design. Wildtype ERK2, MKK6-p38α, and 
MKK7-JNK1 expressed in sufficient yields (Figure 22).  
  
Figure 22: Western blots of ERK2, p38α and JNK1 variants.  
 
In conclusion, the optochemical control of kinase function has been challenging to 
achieve. PCK incorporation in PAK1 was successful, however, caged cdc42 and RhoA were not 
expressed. The kinase activity of PAK1 was photochemically controlled in vitro, but 
transitioning the assay to mammalian cells has not yielded robust results. A retraction of paxillin-
containing focal adhesions has been observed, but more data needs to be collected to further 
examine the role of PAK1 with Rac1 activation and in the MEK1/ERK2 pathways. Ongoing 
work in the optochemical control of MAPKs will hopefully yield three caged kinases that can be 
used to photochemically dissect the regulation signals and feedback loops that are involved in 
those pathways that could not be elucidated without the use of photocaging methodology.  
2.3.3 Experimental  
Generation of pCMV6-FLAG-MKK6-p38α. Phusion PCR was performed on pCMV6-FLAG-
p38α using primers NheI-p38a and p38alpha_HpaI-PCR_Rev and on pCMV6-FLAG-MKK6 
using primers HindIII-FLAG-MKK6 and MKK6-NheI according to the protocol in Section 6.1. 
PCR products were purified using the protocol from Omega PCR Purificatin Kit (Omega). 
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Inserts were then double digested according to Section 6.2 using NheI and HpaI for p38α and 
HindIII and NheI for FLAG-MKK6. After digestion, insert were PCR purified again and then 
ligated together as described in Section 6.2. pCMV6-FLAG-MKK6 was double digested with 
HindIII and HpaI according to Section 6.2, AP treated, and gel purified with a Gel Purificatin kit 
(Omega). The ligated insert, FLAG-MKK6-p38α, was then ligated into pCMV6 according to 
Section 6.2 to generate pCMV6-FLAG-MKK6-p38α.  
 Site-directed Mutagenesis of MAPKs. Constitutively active mutations were introduced 
using the following DNA and primers:  
Table 2: Primer sequences of site-directed mutagenesis of MAPKs. 
Mutation DNA Primer A Primer B 
ERK2 
L74P* 
pCMV6
-HA-
wtERK2 
ERK2 L73P Forw 
(5’- 
AAAATCCTACCCCGCTTCAGA
CATGAGAACATCATCGGCAT
CAATGACATCATC) 
ERK2 L73P Rev (5’- 
TCTGAAGCGGGGTAGGATT
TTTATCTCTCTCAGGGTTCT
CTGACAGTAGGT) 
ERK2 
S151D 
pCMV6
-HA-
ERK2 
L73P 
ERK2 S151D Forw 
(5’- 
CTCAAGCCTGACAACCTCCTG
CTGAACACCACTTGTGATCTC
AAGATCTGTGACTTT) 
ERK2 S151D Rev (5’- 
CAGGAGGTTGTCAGGCTTG
AGGTCACGGTGCAGAACA
TTAGCTGAATGTATATACT
TTAATCC) 
ERK2 
D319N 
pCMV6
-HA-
ERK2 
L73P 
S151D 
ERK2 D319N Forw  
(5’- 
GACCCAAGTAACGAGCCCAT
TGCTGAAGCACCATTCAAGTT
TGACATGGAGC) 
ERK2 D319N Rev (5’- 
AATGGGCTCGTTACTTGGG
TCATAATACTGCTCCAGGT
ACGGGTGGGC) 
p38α 
D176A 
pCMV6
-FLAG-
MKK6-
p38α 
p38alpha D176A Forw  
(5’- 
CACACTGATGCCGAGATGAC
AGGCTACGTGGCTACCAGGT
GGTAC) 
p38alpha D176A Rev (5’- 
TGTCATCTCGGCATCAGTG
TGCCGAGCCAGCCCAAAA
TCCAGAATCTT) 
p38α 
F372S 
pCMV6
-FLAG-
MKK6-
p38α 
D176A 
p38alpha F327S Forw 
(5’GACCAGTCCTCCGAAAGCA
GGGACCTTCTCATAGATGAGT
GGAAGAGCCTGACCTATGAT
GAAGTC) 
p38alpha D327S Rev (5’- 
CCTGCTTTCGGAGGACTGG
TCATAAGGGTCAGCAACA
GGCTCATCATCAGGGTC) 
ERK2 
K52TAG 
pCMV6
-HA-
caERK2 
ERK2 K52TAG Forw  
(5’- 
GCTATCAAGTAGATCAGTTTT
ERK2 K52TAG Rev (5’- 
AGGACTGATCTACTTGATA
GCAACTCGAACTTTGTTGA
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GAGCACCAGACCTACTGT) GATTATCATAAGC) 
JNK1 
K56TAG* 
pCMV6
-FLAG-
MKK7-
JNK1 
Jnk1a1 K55TAG Forw  
(5’-
GCAATCAAGTAGCTAAGCCG
ACCATTTCAGAATCAGACTCA
TGCC)  
Jnk1a1 K55TAG Rev (5’- 
TCGGCTTAGCTACTTGATT
GCAACATTTCTTTCAAGAA
TGGCATCATAAGC) 
 
p38α 
K54TAG* 
pCMV6
-FLAG-
MKK6-
cap38α 
p38alpha K53TAG Forw  
(5’- 
GCAGTTAAGTAGCTGTCGAG
ACCGTTTCAGTCCATCATTCA
CG) 
p38alpha K53TAG  
Rev (5’- 
TCTCGACAGCTACTTAACT
GCCACACGATGCCC) 
Mutations that were incorrect due to primer design are indicated with an asterisk (*).  
 Western Blotting of MAPKs. HEK293T cells were maintained as described in Section 
6.5 and split the day before transfection as described in Section 6.6. Transfection was performed 
with 2 µg of pCMV6-HA-wtERK2, pCMV6-FLAG-MKK6-p38α, or pCMV6-FLAG-MKK7-
JNK1 using the LPEI transfection protocol found in Section 6.6. Cells were incubated overnight 
at 37 ˚C/5% CO2. The next day cells were washed with 1 mL of PBS and lysed with 250 µL of 
kinase lysis buffer (Appendix A). Cells were shook on ice of 20 minutes and lysates were 
centrifuged to 20 minutes at 15,000 rpm/21,130 × g. Western blot was performed as described in 
Section 00 with rabbit anti-HA (Cell Signaling) and a rabbit anti-GAPDH (Santa Cruz) or mouse 
anti-FLAG (Sigma) and mouse anti-GAPDH antibodies (Santa Cruz) depending on the tag 
indicated above at a 1:1000 dilution. Secondary antibody was goat anti-rabbit-HRP and goat 
anti-mouse-HRP (Santa Cruz) diluted 1:30,000 in TBST. Protein bands were detected by 
chemiluminescence as described in Section 6.9.  
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3.0  OPTOCHEMICAL CONTROL OF MEMBRANE LOCALIZATION 
Localization of proteins within mammalian cells is important for proper function. For example, 
transcription factors must be transported into the nucleus and many signaling molecules need to 
be transported to the cell membrane in order to perform their respective functions properly.96,97 
The plasma membrane is one specific location within the cell that is home to multiple types of 
proteins, including transport proteins such as ion channels, receptors such as G protein-coupled 
receptors, and signaling proteins such as Ras.98-100 Each cell type requires a different set of 
proteins to be localized to specific domains within the membrane at specific times in order for 
the cell to function properly.101 The differences in the localization of proteins contribute to the 
diversity of cells and also allows one protein to function in multiple aspects.102 The 
mislocalization of proteins has been determined to be a cause of diseases such as cystic fibrosis, 
kidney disease, and cancer.102-105 While there are multiple reasons why a protein is translocated 
to the membrane, such as extracellular stimuli or cellular feedback loops, protein are located at 
the membrane through transmembrane domains, signaling peptides, fatty acid anchors, and lipid 
anchors.101,106 Post-translational modifications of these signaling sequences with fatty acid 
residues are one mechanism for protein localization to the membrane (Table 3).  
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Table 3: List of fatty acid modifications. Adapted by permission from Macmillan Publishers Ltd: Nature Chemical 
Biology. Resh, M. D. Trafficking and signaling by fatty-acylated and prenylated proteins. 2, 584-590, copyright 
2006. 
 
 
3.1 OPTICAL CONTROL OF MEMBRANE LOCALIZATION THROUGH CAAX 
DOMAIN CAGING 
3.1.1 Introduction to Protein Farnesylation 
One signaling sequence that is post-translationally modified to direct proteins to the 
cellular membrane is the CaaX domain. The CaaX domain consists of a cysteine (C) that is 
alkylated, two aliphatic amino acids (xx), and a C-terminal amino acid (X) that determines the 
type of modification, either farnesylation or gernylgernylation.97 CaaX domain processing 
proceeds as shown in Figure 23.107,108 Prenylation (farnesylation or geranylgeranylation) occurs 
in the cytosol by farnesyl transferase (FTase). Farnesylated proteins are transported to the 
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endoplasmic reticulum where the aaX sequence is cleaved by Ras converting enzyme 1 (Rce-1) 
and carboxylmethylated by Isoprenylcysteine carboxyl methyltransferase (Icmt). At this point 
the pathways diverge depending on a second signaling sequence upstream of the CaaX domain: 
1) proteins with a poly-basic region are transported directly to the membrane via an unknown 
pathway, due to their polylysine-rich second signaling sequence.109 2) proteins with a second 
signal of palmitoylation are transported to the Golgi where a palmitoyl-transferase attaches a 
palmitoyl group the cysteines up-stream of the farnesylated cysteine.110 From the Golgi, the 
farnesylated and palmitoylated proteins are transported to the membrane through the exocytic 
pathway.111 Membrane localization of these proteins is reversible due to the labile thioester 
linkage between the cysteine and palmitoyl group.108 
 
Figure 23: Processing of Ras proteins due to CaaX domains. Adapted with permission from Journal of Lipid 
Research. Wright, L. P.; Philips, M. R. J Lipid Res 2006, 47, 883.  
 
 H-Ras and K-Ras are two important signal transduction proteins with CaaX domains. 
They are members of the Ras superfamily of GTPases. This superfamily can be further broken 
down into six subfamilies: Ras, Rho, Rab, Ran, Rad and Arf, that collectively contain over 50 
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GTPases.112 Ras GTPases are involved in signal transduction as a response to extracellular 
stimuli such as growth factors, cytokines, hormones and neurotransmitters that results in 
synthesis and translocation of proteins, vesicular trafficking, cell proliferation, differentiation, 
apoptosis, cell cycling and nuclear import.113-115 All members of the Ras superfamily cycle 
between active-GTP bound and inactive-GDP bound conformations.116 GTP-bound Ras interact 
with GTPase-activating proteins (GAPs) to increase the rate of GTP hydrolysis and convert Ras 
to its inactive form. Guanine nucleotide exchange factor proteins (GEFs) then aid in the release 
of GDP and re-activation of the GTPase with the addition of GTP. Each cycle of GTP hydrolysis 
acts as a signaling event from stimuli to downstream effectors.117 All members of the Ras 
superfamily are posttranslationally modified to be directed to the cell membrane,118 because 
membrane localization is necessary for proper fuction.119  
The Ras subgroup of proteins is comprised of four isoforms: H-Ras, N-Ras, K-Ras4A 
and K-Ras4B that are 90% homologous except for the 25 C-terminal amino acids, known as the 
hypervariable region. The section is only 10-15% homologous and is likely to determine the 
biological differences, such as effector preference, between the isoforms, Figure 24.109,118 Within 
the hypervariable region, there is the CaaX box, and the linker region upstream of the CaaX 
domain direct H-Ras and K-Ras to the plasma membrane.110 The X position is a serine in H-
Ras120 and a methionine in K-Ras a methionine110 leading to farnesylation of the terminal 
cysteine of both proteins. K-Ras has a poly-basic second signaling sequence, which allows for 
translocation of K-Ras to the membrane through the first scenario described above. H-Ras has a 
second signaling sequence that requires palmitoylation. The two upsteam cysteines from the 
farnesylated cysteine are palmitoylated at the Golgi and H-Ras is transported to the membrane 
through the exocytic pathway.109 
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Figure 24: Sequence homology of Ras GTPases. The hypervariable region is shown in detail. The red cysteines are 
palmitoylated. The red and underlined lysine residues are the second signal for K-Ras4B. The last cysteine residue 
in each sequence is farnesylated. Adapted with permission from Journal of Cell Science. Prior, I. A.; Hancock, J. F. 
J Cell Sci 2001, 114, 1603. 
 
 
Once H-Ras and K-Ras are translocated to the plasma membrane, they localize to 
different areas.109 It was first seen that H-Ras signaling, but not K-Ras signaling, is interrupted 
when the concentration of cholesterol in the membrane is perturbed.121 Prior et al. went on to 
investigate the sites of membrane localization and found that K-Ras exclusively operates in the 
disordered regions of the cell membrane. While for H-Ras, it was determined that the GTP/GDP 
binding state dictates the microdomain of the plasma membrane that it resides in.122 Upon 
farnesylation and palmitoylation, H-Ras is targeted to cholesterol-rich lipid rafts and caveolae. 
However, H-Ras is being reallocated to disordered regions upon activation through binding of 
GTP. The equilibrium shift from lipid rafts to disordered regions contributes to the increased 
efficiency of Ras effector activation. The lateral movement within the membrane and increased 
activation could be due to the conformational change of H-Ras when it is bound to GTP, which 
exposes specific residues within the hypervariable region that favor interactions with the 
disordered regions of the membrane and also allow for more favorable interactions with effector 
proteins.118,123 Early on it was speculated that Ras effectors were localized in the disordered 
region lending to the equilibrium shift for Ras-GTP.122 However, recent studies has not been able 
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to prove this as the major reason for reallocation, but only that the hypervariable region is 
necessary for movement.118,122  
H-Ras and K-Ras contain a lysine residue directly upstream of the farnesylated cysteine, 
leading to the hypothesis that membrane localization could be optochemical controlled through 
the replacement of this lysine residue with PCK. The photochemical control of H-Ras and K-Ras 
membrane localization will allow for the elucidation of the kinetics of these processes because a 
starting point can be generated through light exposure. Furthermore, the caged CaaX domain 
could be used with any protein of interest to temporal control its membrane localization. This 
could be useful for investigation of protein function based upon localization.  
3.1.2 Previous Approaches to Optically Control Membrane Localization and the 
Farnesylation Pathway  
Membrane localization has been previously optochemically controlled through the use of caged 
small molecule protein dimerizers, such as rapamycin.45,124 Chapter 5.0 describes examples of 
this approach. Phytochromes and crytochromes have also been used to control membrane 
localization with light.38, 125 These approaches are described in Chapter 1.0    
An example of using photocaging to control FTase function was reported in 2012 using a 
caged FTase inhibitor.126 A FTase inhibitor, FTI, was chemically modified with a 
bromohydroxycoumarin-caging group at an essential thiol, Figure 25A. Its activity was measured 
through the detection of H-Ras and ERK (a target of H-Ras) phosphorylation (Figure 25B). H-
Ras is only phosphorylated (and activated) when properly translocated to the membrane, a 
process that it is inhibited by FTI. As seen in Figure 25B, the caged Bhc-FTI is completely 
inactive allowing H-Ras and ERK phosphorylation. However, after Bhc-FTI exposure to UV 
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light and decaging, FTase and thereby H-Ras translocation is inhibited, leading to the inhibition 
of H-Ras and ERK phosphorylation. 
To further confirm that Bhc-FTI was acting as expected, membrane localization of a 
GFP-H-Ras fusion was used as a readout (Figure 25C-H). In agreement with the Western blot 
results, Bhc-FTI is inactive, leading to GFP-H-Ras farnesylation and exclusive membrane 
localization (Figure 25E). However, light-induced FTI decaging inhibits FTase and leads to the 
retention of some GFP-H-Ras in the cytoplasm (Figure 25F). Inhibition of membrane 
translocation is more pronounced in the treatment with non-caged FTI.  
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Figure 25: Photocaged FTase inhibitor and functional assays. A) Structure of caged FTase inhibitor, Bhc-FTI. B) 
Western blot assay of ERK phosphorylation by H-Ras in conjunction with Bhc-FTI. GFP-Ras localization C) in the 
presence of 0.2% DMSO. D) in the presence of 1 µM FTI (non-caged FTase inhibitor). E) in the presence of 5 µM 
Bhc-FTI. F) in the presence of 5 µM Bhc-FTI with UV irradiation. G) with UV irradiation. H) 5 µM FTI.  
 
While the examples presented above are good examples of using caging groups on small 
molecule effectors of enzymes and using light sensitive protein fusions, the caging of proteins 
and protein substrates of the CaaX processing pathway represents a more direct way of 
controlling its function with light.  
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3.1.3 Incorporation of PCK into CaaX domains for the Optical Control of Membrane 
Localization 
To facilitate the visualization of CaaX box-tagged proteins, an EGFP fusion was  chosen.127, 128, 
129, 130, 131 DNA encoding the ten C-terminal amino acids (GCMSCKCVLS) of H-Ras were 
cloned onto the C-terminus of EGFP.131 Total internal reflection fluorescence (TIRF) microscopy 
was used to image only the membrane-localized protein.132 This technique is widely used to 
study processes that are occurring at the cell membrane. As expected, membrane localization of 
EGFP was observed when the plasmid encoding EGFPc10HRas was transfected into cells 
(Figure 26A). Upon introduction of a TAG mutation at the K6 codon and expression in the 
presence of PCK, membrane localization was no longer observed (Figure 27A), in agreement 
with a negative control expression in the absence of PCK (Figure 26C). By not supplying the 
cells with caged lysine, translation will halt at the TAG mutation, leading to EGFP expression 
without a functional CaaX domain and localization in the cytosol. As expected, irradiation of the 
positive and negative control (365 nm, 20 sec) did not induce significant changes in fluorescence 
intensity (Figure 26B and D). Thus, the UV light did not have non-specific effects of EGFP 
localization. 
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Figure 26: TIRF images of EGFPc10HRas. pEGFPc10HRas expressed in HeLa cells A) before and B) after 
irradiation. pEGFPc10HRas K6TAG without PCK expressed in HeLa cells C) before and D) after irradiaiton. 
Images were taken with a prism-based TIRF microscope that was built around a Zeiss Axioskop 2 FS by the Haugh 
Lab (NCSU). A 40X (0.8 NA Achroplan; Zeiss) objective was used and GFP was excited at 488 nm. Images were 
collected using MetaMorph software. Yellow/red pseudo color represents high membrane fluorescence, while 
blue/purple pseudo-color represents low membrane fluorescence. 
 
HeLa cells were transfected with a plasmid encoding EGFPc10HRas K6TAG and the 
PCKRS and a plasmid encoding the PylT in the presence of PCK (1 mM). Cells were imaged for 
20 min before irradiation and after irradiation (365 nm, 20 sec) for 60 min (Figure 27A). The 
increase in fluorescence before irradiation may be due to the fluctuation in the cells during 
temperature equilibration at the beginning of imaging experiments. Imaging experiments began 
10-15 minutes after cells were placed on the incubated stage. Membrane fluorescence 
dramatically increases after irradiation, as seen when plotting fluorescence intensity versus times 
(Figure 27B). The resulting graph was fitted to a first-order exponential reaction equation, 
revealing a rate constant of 0.0492 s1- and a lag time of ~3 minutes after irradiation. Fluorescence 
intensity reaches a plateau after 50-60 minutes. The reaction kinetics of CaaX domain-mediated 
membrane localization have not been investigated before the presented work, as it was 
impossible to define the start point of the translocation process. The kinetics of FTase and 
before 
irradiation 
after 
irradiation A B 
C D 
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palmitoyltransferase have been determined,133,134 however, the kinetics of membrane localization 
in its entire process have not been elucidated. The obtained results demonstrate that translocation 
of CaaX box-tagged EGFP containing a K6→PCK mutation can be controlled by light. Thus, 
before irradiation the presence of the caging group either prevents the addition of the farnesyl 
group or restricts the processing of the CaaX box at later stages of the pathway shown in Figure 
23. Based on the crystal structure of FTase, it is possible that caging K6 interrupts the exit 
mechanism of the farnesylated protein.135 The lysine-6 residue seemingly points away from the 
reaction pocket. For these reasons, it is difficult to predict with certainty that farnesylation is the 
process that is being controlled with the substitution of the lysine-6 position with PCK. 
 
  
Figure 27: Optical control of membrane localization using a caged CaaX domain, CVLS. A) Representative TIRF 
microscopy images of EGFPc10HRas K6TAG in the presence of PCK (1 mM). Images were taken with a prism-
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based TIRF microscope that was built around a Zeiss Axioskop 2 FS by the Haugh Lab (NCSU). A 40X (0.8 NA 
Achroplan; Zeiss) objective was used and GFP was excited at 488 nm. Cells were irradiated at time point 0 for 20 
seconds using a DAPI filter (excitation 365/50 nm). Images were collected using MetaMorph software. B) Relative 
fluorescence vs. time plot of TIRF microscopy observation of EGFPc10HRas K6TAG. t=0 is the point of 
irradiation. Three independent cells were observed The purple plot is an exponential fit.  
 
After successfully controlling protein membrane translocation using a caged H-Ras CaaX 
sequence, additional positions were investigated for optical control using PCK. Hougland et al. 
had studied a variety of CaaX box sequence as substrates for FTase.136 Two CaaX boxes, one 
with lysine in the a1 position (CKIS) and one with the lysine in the a2 position (CTKF), were 
found to be functional in translocating to the membrane. Thus, the previously used EGFPc10H-
Ras constructs were mutated to CKIS and CTKF CaaX domains. When transfected into HeLa 
cells, EGFPc10HRas CKIS produced a membrane bound EGFP phenotype, while CTKF did not 
(Figure 28). 
  
Figure 28: HeLa cells transfected with plasmids encoding CaaX domain variants. A) EGFPc10HRas CKIS B) 
EGFPc10HRas CTKF. Cells were imaged 24 hours after transfection using a Zeiss Observer Z1 microscope using 
the 40X objective with the GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
 
A K8TAG mutation was introduced into EGFPc10HRas CKIS and positive and negative 
control experiments were performed with EGFPc10HRas CKIS and EGFPc10HRas C-K8TAG-
IS in the absence of caged lysine. As expected, EGFPc10HRas CKIS was targeted to the 
membrane and strong fluorescence was seen before and after a 20 second irradiation at 365 nm, 
(Figure 29A and B), while the K8TAG mutant did not lead to any membrane fluorescence 
(Figure 29C and D). Irradiation had no effect on EGFP localization.  
A B 
 52 
  
Figure 29: TIRF images of EGFPc10HRas CKIS. pEGFPc10HRas CKIS expressed in HeLa cells A) before and B) 
after a 20 second UV irradiation using a DAPI excitation filter (365/50 nm). pEGFPc10HRas C-K8TAG-IS without 
PCK expressed in HeLa cells C) before and D) after irradiaiton. Images were taken with a prism-based TIRF 
microscope that was built around a Zeiss Axioskop 2 FS by the Haugh Lab (NCSU). A 40X (0.8 NA Achroplan; 
Zeiss) objective was used and GFP was excited at 488 nm. Images were collected using MetaMorph software. 
 
The EGFPc10HRas CK8TAGIS system was then employed in light-activation 
experiments identical to the EGFPc10HRas K6TAG system (Figure 30). A rate constant of 
0.0178 s1- and a lag time of ~13 minutes after irradiation was obtained first-order exponential 
kinetics. The increased lag time is most likely a result of the CaaX box mutation. Hougland et. 
al. reported that this substrate has a kcat/Km value an order of magnitude lower than other 
substrates in their experiments. However, they did not exam the translocation rate of the wild-
type H-Ras CaaX sequence.136 
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Figure 30: Optical control of membrane localization using a caged CaaX domain, CKIS. A) TIRF microscopy 
micrographs of HeLa cells expressing EGFPc10HRas C-K8TAG-IS in the presence of PCK (1 mM). Images were 
taken with a prism-based TIRF microscope that was built around a Zeiss Axioskop 2 FS by the Haugh Lab (NCSU). 
A 40X (0.8 NA Achroplan; Zeiss) objective was used and GFP was excited at 488 nm. Irradiation was performed at 
time point 0 for 20 seconds using a DAPI excitation filter (365/50 nm) Images were collected using MetaMorph 
software. B) Relative fluorescence vs. time plot of TIRF microscopy observation of EGFPc10HRas C-K8TAG-IS 
t=0 is the point of irradiation. Three independent cells were observed and the data was plotted. The purple plot is an 
exponential fit. 
 
These studies were then extended to the K-Ras CaaX box and its second signal consisting 
of a polybasic region. DNA encoding the 14 C-terminal amino acids (KKKKKKSKTKCVIM) 
of KRas was hybridized131 and inserted downstream of EGFP, generating EGFPc14KRas. 
Transfection of the construct into HeLa cells produced membrane-targeted EGFP expression 
(Figure 31A). Mutation of K10 to TAG and expression of EGFPc14KRas K10TAG in the 
presence of PCK, lead to substantial variation between experiments, (Figure 31C). Relative 
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fluorescence was determined by dividing fluorescence intensity at each time point by the 
fluorescence intensity at the point of irradiation, thus allowing change to be compared. However, 
no clear trend was observed and caging of K10 in the K-Ras CaaX domain did not allow for 
robust photocontrol of protein translocation. 
 
Figure 31: HeLa cells transfected with a plasmids encoding K-Ras CaaX domain. A) EGFPc14KRas B) 
EGFPc14KRas K10TAG in the presence of PCK (1 mM). Cells were imaged 24 hours after transfection using a 
Zeiss Observer Z1 microscope using the 40X objective with the GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
Cells were irradiated for 20 seconds at time point 0 using a DAPI excitation filter (365/50 nm).  
 
It was next sought to determine what CaaX-modifying enzyme was inhibited by the 
presence of PCK. It was hypothesized that FTase was being blocked from adding the farnesyl 
group.137 In order to test this hypothesis, an alkyne modified farnesol group was used, 
C15AlkOH (Figure 32).138 If FTase is functional, C15AlkOH will be attached in place of a 
wild-type farnesyl group on the cysteine of the protein of interest. Cell lysates can be reacted 
with an azide-conjugated dye labeling modified proteins. 
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Figure 32: Structure of alkyne modified farnesol group, C15AlkOH.  
 
HEK293T cells were transfected with pPCKRS-EGFPc10HRas or pPCKRS-
EGFPc10HRas K6TAG and pPylT, and were incubated in the presence of PCK (2 mM). All 
samples were exposed to 50 µM of lovastatin and 25 µM of C15AlkOH. Cells were lysed after 
24 h and a click reaction was performed with an azide-rhodamine dye. SDS-PAGE analysis 
revealed that EGFP was present in the EGFP-CaaX and caged EGFP-CaaX samples (Figure 33); 
however, no selective rhodamine labeling of EGFPc10HRas was observed and bands occurred in 
all samples, precluding further studies of the farnesylation status of H-Ras. 
 
Figure 33: EGFP and rhodamine fluorescence from lysates of HEK293T cells treated with 50 µM lovastatin and 25 
µM C15AlkOH during transfection with linear PEI. Click reaction with rhodamine-azide was performed after cell 
lysis. 
 
In conclusion, optical control of membrane localization was achieved through the 
incorporation of PCK at position K6 in the CaaX domain of H-Ras, and at position K8 of the 
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CaaX domain of Rab. Optical control of membrane localization through the caging of the K-Ras 
CaaX domain was not successful. This is the first time that the kinetics of the CaaX domain-
processing pathway have been determined as a whole. Previously, individual enzymes have been 
investigated, but there was no technology available to explore the pathway in a cellular setting. 
Optical control through unnatural amino acid mutagenesis has made this possible as it allows for 
temporal control and a defined starting point for kinetic measurements. The precise mode of 
action of inhibition of translocation through strategically placed PCK into the CaaX domain still 
remains elusive. 
3.1.4 Experimental  
Cloning of pPCKRS-EGFPc10HRas. The 10 C-terminal amino acids of HRas were added to 
EGFP by Phusion PCR (Section 6.1). The reverse primer had the following nucleotide sequence: 
5’- GCATCAATTGTCAGGAGAGCACACACTTGCAGCTCATGCAGCCCTTGTACAGCTC 
GTCCATG. The underlined sequence is that of H-Ras. pPCKRS and the EGFPc10HRas insert 
were double digested with NheI and MfeI and gel purification or PCR purification, respectively, 
were performed. The single stranded DNA fragments were then ligated together and 
transformed. Colonies were grown in LB Broth overnight, the pPCKRS-EGFPc10HRas plasmid 
was isolated and confirmed by sequencing.  
Site-directed Mutagenesis to Generate pPCKRS-EGFPc10HRas K6TAG. The 
K6TAG mutation (primers: forward 5’-CTGCATGAGCTGCTAGTGTGTGCTCTC; reverse 5’-
GAGAGCACACACTAGCAGCTCATGCAG) was introduced into pPCKRS-EGFPc10HRas 
using the QuikChange Lightening kit (Agilent Technologies, Inc).  
 
 57 
Live Cell TIRF Imaging. HeLa cells were cultured as indicated in Section 6.5 and 
seeded in a 6 cm plate the day before transfection using 1.5 mL of cells (~1 × 106 cells) and 3.5 
mL of fresh DMEM. Cells were transfected with 5 µg of pPCKRS-EGFPc10HRas K10TAG (or 
the wild type CaaX domain) and 5 µg of pPylT (if necessary) using 37.5 µL of LPEI and the 
protocol in Section 6.6. Twenty-four hours post-transfection, media was removed and the cell 
were trypsinized using 1 mL of TrypLE (Gibco). Cells were centrifuged for 10 minutes at 1000 
rpm and resuspended in 1 mL of phenol red free DMEM. Cells were counted and 50,000 cells 
were plated onto a poly-lysine coated cover slip with a PVC ring attached with grease. Cells 
were incubated for 3 hours at 37 ˚C/5% CO2, and TIRF imaging was conducted by the Haugh 
Lab. Imaging parameters can be found in the captions of specific images. Fluorescence 
intensities were determined by Shoeb Ahmed in the Haugh Lab in regions of interest inside the 
cells (ImageJ, NIH).  
Metabolic Labeling Using C15AlkOH. HEK293T cells were maintained as indicated in 
Section 6.5. Cells were seeded in a 6-well plate as indicated in Section 6.6. HEK293T cells were 
transfected with 1 µg of pPCKRS-EGFPc10HRas or pPCKRS-EGFPc10K10HRas and 1 µg of 
pPylT using the LPEI protocol in Section 6.6. All samples had 25 µM C15AlkOH present and 
and 25 µM lovastatin. Cells were incubated for 24 hours and then lysed with 200 µL of lysis 
buffer (PBS with 0.1% SDS, 0.2% Triton X-100, 2.4 µM PMSF and protease cocktail inhibitor). 
An aliquot of the lysates (25 µL) were combined with 100 µM rhodamine-azide (synthesized by 
Meryl Thomas in the Deiters Lab, Figure 34), 1 mM TCEP, 100 µM TBTA, and 1 mM CuSO4 
and incubated for 2 hours at room temperature while shaking. Protein loading dye was added and 
samples were loaded on a 10% SDS-PAGE gel. The gel was imaged for GFP and rhodamine 
fluorescence  
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Figure 34: Structure of rhodamine-azide for metabolic labeling.  
 
 
 
3.2 OPTICAL CONTROL OF MEMBRANE LOCALIZATION USING SH4 
DOMAINS 
3.2.1 Introduction 
Protein tyrosine kinases are an integral part of signaling pathways and are typically associated 
with transmembranre receptors.139 Src family kinases (SFKs) are a group of nonreceptor protein 
tyrosine kinases with nine members, Src, Lck, Hck, Fyn, Blk, Lyn, Fgr, Yes, and Yrk.140 SFKs 
have been implicated in multiple cellular functions including cell poliferation, cytoskeletal 
alterations, differentiation, survival, adhesion, and migration.141 The structure of SFKs is 
composed of six regions: the Src homology (SH) 4 domain, the unique region, the SH3 domain, 
the SH2 domain, the kinase domain, and a regulatory C-terminal domain (Figure 35).140  
 
 
rhodamine-azide 
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Figure 35: Structure of SFKs. The dark blue domain is the SH4 domain and controls membrane localization of 
SFKs. 
 
The unique region of SFKs is the only distinct region within SFKs and is implicated in 
determining the specific binding partners of each of the kinases within the family. The SH3 
domain is responsible for interactions with substrates by recognition of proline-rich sequences 
and is an integral part of SFKs’ regulation. The SH2 domain recognizes phosphotyrosine and the 
amino acids C-terminal to the tyrosine to distinguish binding partners. The kinase domain of 
SFKs is comprised of two lobes: the N-terminal lobe is the smaller of the two and plays a part in 
the regulation of SFKs, and the larger C-terminal lobe aids in tyrosine phosphorylation. The ATP 
binding and phosphorylation takes place in the cleft between the lobes. The final region, the C-
terminal regulatory domain, contains a tyrosine (Y527 in Figure 35) that can be phosphorylated. 
When phosphotyrosine is present, the SH3 and SH2 adopt a conformation that secures the kinase 
domain in an inactive state. Activation of SFKs occurs through binding of SH2 and/or SH3 
domains to their binding partners, interrupting the intramolecular interactions and 
phosphorylation of Tyr416.  
The presented research will focus on the SH4 domain of Fyn and Src. The SH4 domain is 
a 14 to 16-amino acid sequence on the N-terminal of SFKs that is modified for plasma 
membrane targeting.141 All SFKs have a myristate group added to the N-terminus after removal 
of the methionine in position one. A glycine in position two is necessary for addition of the 
myristate and N-myristyltransferase prefers a serine or threonine in position six.142 As in case of 
the Ras proteins, a second signal is required for translocation to the plasma membrane. The 
second signal is palmitoylation at C3 for Fyn and a polybasic region for Src. Myristoylation 
occurs co-translationally via formation of a stable amide bond, while palmitoylation is a 
reversible post-translational modification via a thioester bond.143 Fyn and Src have lysine 
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residues in the 7 and 9 position, and Src has an additional lysine in the 5 position. It was found 
that mutations of K7 and K9 in Fyn reduce membrane association due to inefficient 
myristoylation,144 and mutation of K7 in Src also reduces membrane targeting.145 It was later 
discovered that K7 and K9 of Fyn are trimethylated after myristoylation and palmitoylation.146 
Using this information, we hypothesized that membrane translocation could be controlled with 
light by incorporating the caged lysine PCK at positions 7 and 9 in Fyn. It also sought to control 
translocation and determine the role of K5 and K9 in Src. Src family kinases are a part of 
multiple signaling pathways that have yet to be completely elucidating.141 Using photocaged 
SH4 domains, Fyn and Src can be activated with precise spatial and temporal control allowing 
for defined cellular responses to be observed and pathway connections to be clarified. 
 
3.2.2 Incorporation of PCK into the SH4 domains of Fyn and Src for Optical Control of 
Membrane localization 
DNA oligos encoding the sixteen N-terminal amino acids of Fyn (MGCVQCKDKEATKLTE)146 
and of Src (MGSSKSKPKDPSQRRR)143 were annealed and ligated to the N-terminus of the 
EGFP gene and the remaining internal ATG start codon (M22) of EGFP was silenced through 
mutation to GGG to encode for the incorporation of glycine. Expression of these mutants showed 
defined membrane localization of EGFP before introduction of a TAG mutant (Figure 36). 
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Figure 36: Schematic of SH4 domain tagged EGFP and expression in HeLa cells. A) Fyn16EGFP. B) Src16EGFP. 
Images were taken using a Zeiss Observer Z1 microscope with a 63X objective (NA 1.40 oil/plan-apochromat; 
Zeiss) and a GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
 
 Photochemical control was then attempted with these constructs. First, a TAG mutation 
was introduced at K7 of Fyn, and K5 and K9 of Src. Plasmids encoding these mutants as well as 
PylRS and PylT were transfected into HeLa cells in the presence and absence of PCK under 
multiple conditions (Figure 37). As expected, no fluorescence was observed in the absence of 
PCK for all constructs (Figure 37F-J). Increasing the amount of pPylT from 100 ng to 200 ng 
resulted in promising expression of Fyn16EGFP K7TAG (Figure 37B). However, membrane 
localization before irradiation is seen in both samples. This likely indicates that mutation of one 
lysine residue within the Fyn SH4 domain does not disrupt the membrane localization. 
Previously literature has shown that mutation of one residue does reduce the membrane 
localization some, but mutation of both K7 and K9 together displays maximal suppression.144 
The expression of Src SH4 domain tagged EGFP was optimal for K5TAG PCK (Figure 37C). 
A B 
EGFP Src16 
MGSSK5SK7PK9DPSQRRR 
EGFP Fyn16 
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Figure 37: Expression of EGFP fused with caged SH4 domains. A) and F) Fyn16EGFP K7TAG with PCK (2 mM) 
and B) and G) 200 ng of the PylT plasmid and PCK (1 mM), C) and H) Src16EGFP K5TAG with PCK (2 mM) and 
D) and I) with PCK (5 mM) and E) and J) Src16EGFP K9TAG with PCK (1 mM) in HeLa cells. All samples were 
transfected with 100 ng of pPylT unless otherwise indicated. Images were taken using a Zeiss Observer Z1 
microscope with (A and B) 40X objective (NA 0.75 /EC plan-apochromat; Zeiss) (C-E) 20X (NA 0.8 / plan-
apochromat) and a GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
 
The first attempt to photochemically control membrane localization with a caged SH4 
domain used the Fyn16EGFP K7TAG construct and the optimal conditions (Figure 37B). HeLa 
cells were transfected with a plasmid encoding Fyn16EGFP K7TAG and the PCKRS and a 
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plasmid encoding the PylT (200 ng) in the presence of PCK (1 mM). Twenty-four hours post-
transfection, cells were imaged for expression and then irradiated for 30 seconds using a DAPI 
filter and imaging was continued for 40 minutes (Figure 38). No translocation was seen during 
this time. Before irradiation, cytosolic EGFP was observed, allowing for the assumption that 
Fyn16EGFP K7TAG was not processed properly and one or more of the myristoylation, 
palmitoylation, or methylation events did not occur. This is different from the results seen in 
Figure 37. Previously, some membrane localization was seen when the plasmid was used, 
however during this experiment ubiquitous EGFP fluorescence was seen. After irradiation and 
decaging, membrane-targeting activity was not restored and EGFP was not localized to the 
membrane. This experiment was tried multiple times in two different cells types, KNRK and 
HeLa cells, with different irradiation durations, 15 seconds, 30 seconds, 1 minute, and 2 minutes,  
and no translocation was observed using this imaging setup. It is possible that using confocal 
microscopy or TIRF microscopy would show membrane localization after irradiation.   
  
Figure 38: Photochemical control of Fyn16EGFP K7TAG in the presence of PCK (1 mM). Cells were irradiated at 
t=0 for 30 seconds at 365 nm using a DAPI filter. Images were taken using a Zeiss Observer Z1 microscope with a 
40X objective (NA 0.75/ EC plan-apochromat; Zeiss) and a GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
 
t=0 min t=5 min t=20 min t=15 min t=10 min 
t=30 min t=25 min t=35 min t=40 min 
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Src16EGFP K5TAG was then investigated by transfecting HeLa cells with a plasmid 
encoding Src16EGFP K5TAG and PCKRS and pPylT in the presence of PCK (2 mM) (Figure 
39). After the media was replace to remove PCK, cells were irradiated for 15-120 sec at 365 nm 
(DAPI filter) through a 20X objective using the microscope Xe/Hg lamp and then incubated for 
24 h. Cells were then imaged for translocation of EGFP to the membrane (Figure 39E-H). Slight 
membrane localization can be seen in the cells that have been irradiation for 30 and 60 seconds 
(Figure 39F and G). Unfortunately, this translocation is not as pronounced as hoped. More 
noticeable membrane localization could potentially be seen if microscopy techniques such as 
confocal microscopy or TIRF were used. Translocation kinetics of SH4 domains are not easily 
determined because modification are done co-translationally.97 For this reason, it is difficult to 
know how long it will take a caged SH4 domain to translocate to the nucleus. There is some 
literature evidence that newly synthesized SH4 domain-tagged proteins are trafficking to the 
membrane within an hour.147 
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Figure 39: Expression of Src16EGFP K5TAG in HeLa cells before and 24 hrs after indicated irradiation times. 
Irradiation was performed using a DAPI filter (365/50 nm). Images were taken using a Zeiss Observer Z1 
microscope with a 63X objective (NA 1.40 oil/plan-apochromat; Zeiss) and a GFP (38 HE) filter (ex: BP470/40; 
em: BP525/50). 
 
Src16EGFP K7TAG and Src16EGFP K9TAG were also investigated for photochemical 
control of translocation (Figure 40). Cells were irradiated for 15 seconds and again, no 
translocation of EGFP was seen for K7TAG or K9TAG after 24 hours.  
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Figure 40: Expression and irradiation of Src16EGFP K7TAG and Src16EGFP K9TAG. Cells were transfected with 
the Src and PCKRS expression plasmid as well a pPylT with PCK (2 mM). Cells were irradiated with a DAPI filter 
(365/50 nm) Images were taken using a Zeiss Observer Z1 microscope with a 63X objective (NA 1.40 oil/plan-
apochromat; Zeiss) and a GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
 
Disruption of membrane localization through the caging of lysine residues within the Fyn 
and Src SH4 domain was not surprising as it is reported previously that mutation of K7 of Src 
and K7 and K9 of Fyn causes reduced membrane localization.146 However, it is not clear why 
after decaging localization to the membrane was not restored. If only small amounts of protein 
are decaged and translocate to the membrane, epi-fluorescent imaging will not be sufficient to 
detect this and TIRF microscopy could be used as it is more sensitive to activity at the 
membrane.132 Another explanation could be the fact that N-myristolyation occurs during protein 
synthesis,97 and not-postranslationally. However, light-induced PCK decaging can only be 
conducted after protein synthesis is complete.  
3.2.3 Experimental 
Cloning of pPCKRS-EGFP plasmids with N-terminal SH4 domains. pEGFP-N1 was double 
digested with NheI and AgeI, treated with Antarctic Phosphatase, and gel purified. Purchased 
inserts for Fyn16 and Src16 were ligated into double digested pEGFP-N1. Fyn16EGFP (Primers: 
forward 5’-CTAGCATGGGCTGTGTGCAATGTAAGGATAAAGAAGCAACAAAACTGAC 
Src16EGFP 
K7TAG  
before after 
Src16EGFP 
K9TAG  
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GGAGGGA; reverse 5’- CCGGTCCCTCCGTCAGTTTTGTTGCTTCTTTATCCTT 
ACATTGCACACAGCCCATG) and Src16EGFP (Primers: forward 5’-  
CTAGCATGGGTAGCAACAAGAGCAAGCCCAAGGATGCCAGCCAGCGGCGCCGCGG
A; reverse 5’- CCGGTCC GCGGCGCCGCTGGCTGGCATCCTTGGGCTTGCTCTTGTTGC 
TACCCATG) inserts were generated by Phusion PCR with NheI and MfeI digestion sites. 
pPCKRS and SH4-domain inserts were double digested and gel purified or PCR purified, 
respectively. Each SH4-EGFP insert was ligated into pPCKRS. Plasmids were confirmed by 
sequencing.  
 Live-cell Imaging. HeLa cells were maintained as described in Section 6.5. The day 
before transfection cells were seeded in an 8-well chamber slide as described in Section 6.6 and 
incubated overnight at 37 ˚C/5% CO2. Cells were transfected with 200 ng total of DNA (200 ng 
of the wild type SH4 domain plasmids or 100 ng of pPCKRS-Fyn16(Src16)EGFP TAG mutants + 
100 ng of pPylT using the LPEI protocol in Section 00. Cells were incubated overnight at 37 
˚C/5% CO2. The next day media was replaced with 200 µL of phenol red free DMEM for 
imaging. Imaging parameters can be found in the captions for specific images.  
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4.0  OPTICAL CONTROL OF PROTEASE ACTIVATED RECEPTOR 2 
4.1.1 Introduction to PAR2 
Protease-activated receptor 2 (PAR2) (also known in the literature as proteinase-activated 
receptor 2) is a member of a family of four G-protein coupled receptors that are embedded in the 
cell membrane.148 PARs are expressed at the plasma membrane and upon cleavage of their 
extracellular N-terminus by serine proteases are irreversibly activated. PAR2 is cleaved by 
trypsin, tryptase, gingipains-R, elastase, cathepsin G and proteinase-3. These serine proteases are 
secreted from the pancreas, microbes and immune cells.149,150, 151 PAR2 is the only PAR that is 
not activated by thrombin. This cleavage exposes a “tethered” ligand sequence that will interact 
with an extracellular loop to induce a confirmation change and further signal transduction 
(Figure 41A). Activation of PARs can also be achieved through use of an activating peptide 
(AP), (Figure 41B). In the absence of proteases, a synthetic peptide with the identical sequence 
of the tethered ligand can be used to activate PARs.152  
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Figure 41: Schematic of PAR2 activation. A) Activation of PAR2 through cleavage of the tethered ligand peptide 
by a protease. B) Activation of PAR2 through binding of an activating peptide.  
 
In addition to downstream signaling, activation of PAR2 induces an increase in cellular 
Ca2+ concentration.153 After repeated exposure to trypsin the cellular concentration of Ca2+ no 
longer was affected due to the uncoupling of the G-protein from PAR2 by protein kinase C, and 
internalization of PAR2 into early endosomes. It was later determined that Ca2+ is necessary for 
PAR2 trafficking as it is required for protein kinase C function and β-arrestins are involved in 
the desensitization of PAR2.150 PAR2 is eventually targeted to lysosomes where is it degraded. 
In order to facilitate further signaling, PAR2 is transported from Golgi storage to the membrane 
or newly synthesized.153  
PARs have been implicated in tissue-damage repair, hemostatsis, cell survival, 
inflammation and pain response.148 PAR2, specifically, is found in the gastrointestinal tract and 
pancreas and regulates the secretion of signaling molecules responsible for inflammatory and 
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anaphylactic reaction response and ion channel activity.150 The tethered ligand sequence of 
PAR2 contains a lysine residue.151  
4.1.2 Incorporation of PCK into PAR2 to Photochemically Control Activation 
It was hypothesized that the PAR2 interaction with the tethered ligand sequence and thus 
activation, translocation, and signaling could be controled with light by replacing the lysine with 
the PCK (Figure 42). Photochemical control of PAR2 activation and translocation will allow the 
investigation of new pathways involving PAR2. Downstream signals can be observed and the 
timing of PAR2 interactions can be determined due to the precise temporal control of PAR2 
activation that is made possible by using light as trigger. 
 
Figure 42: Schematic of optical control of PAR2 activation and localization.  
 
It has been shown that activation and cellular translocation of PAR2 can be followed by 
imaging of a PAR2-EGFP fusion protein.150 Using a PAR2-EGFP construct from the Bunnett 
Lab (UCSF), a full length PAR2-EGFP gene and a truncated-tethered ligand exposed PAR2-
EGFP gene were cloned into a vector containing the PCKRS. Expression of full length PAR2-
EGFP in Kirsten murine sarcoma virus transformed Normal Rat Kidney (KNRK) cells yielded 
membrane localization of PAR2-EGFP as expected when imaged 24-hours post-transfection 
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(Figure 43A). Transfection of a plasmid encoding the tethered-ligand exposed PAR2-EGFP 
(ptPAR2-EGFP) into KNRK cells and imaging 24 hours later showed localization of PAR2-
EGFP in perinuclear vesicles (Figure 43B).150 This is because the tethered ligand sequence is 
exposed in the truncated protein and it is constitutively active.  
 
Figure 43: Phenotype of PAR2 variants in KNRK cells. A) KNRK cell expressing PAR2-EGFP. Full length PAR2 
is localized to the membrane. B) KNRK cell expressing tPAR2-EGFP. Truncated PAR2-EGFP has the tethered-
ligand sequence exposed and therefore is localized to perinuclear vesicles.  
 
Introduction of a TAG mutation at K5 in truncated PAR2-EGFP (tPAR2-EGFP) should 
mask the tethered ligand, sending tPAR2-EGFP to the membrane. Upon irradiation, the tethered 
ligand should become exposed and translocation to perinuclear vesicles should be observed 
(Figure 42). 
When KNRK cells were transfected with pPCKRS-tPAR2-EGFP-K5TAG in the absence 
of PCK, expression was still observed (Figure 44A). However, there is less PAR2-EGFP 
localization either at the membrane or perinuclear vesicles compared to that in the cell in Figure 
43A. When tPAR2-EGFP is expressed (Figure 43B) fluorescence is seen in perinuclear vesicles 
with very little background in other regions of the cells. KNRK cells transfected with pPCKRS-
tPAR2-EGFP-K5TAG and pPylT in the presence of PCK show expression at the membrane, in 
perinuclear vesicles and a higher background in the cytosol (Figure 44B). Unfortunately, 
translocation of membrane localized PAR2-EGFP to perinuclear vesicles after 10 seconds of 
irradiation at 365 nm was never observed. This is likely due to the fact that K5 was found to not 
A B 
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be essential in the tethered linker signaling.154 It was hoped that PCK would be large enough that 
it would sterically block any signaling before irradiation.  
 
Figure 44: Expression of pPCKRS-tPAR2-EGFP-K5TAG with pPylT A) in the absence of PCK and B) in the 
presence of PCK.  
 
In conclusion, substitution of K5 with PCK in the tethered ligand sequence of truncated 
PAR2 did not allow for photochemical control of PAR2 activation and translocation. 
Localization of tPAR2-EGFP K5TAG in the presence of PCK was not exclusively found at the 
membrane as expected, due to incomplete suppression of the TAG mutation or the inability for 
PCK to block the activation of PAR2 as mutation of K5 is reported to reduce PAR2 activation 
by 60%,154   and upon irradiation, translocation of membrane bound tPAR2-EGFP K5TAG to 
perinuclear vesicles was not seen. This is unexpected, as the decaging should allow for 
restoration of the lysine residue and activation comparable to cleavage with trypsin. Based on 
these experiments, a different approach to photochemical control of PAR2 was explored.  
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4.1.3 Caged peptide control of PAR2 
As discussed earlier, PAR2 can be activated by an external peptide with the same sequence as 
that of the tethered ligand. The addition of the activating peptide (AP) induces the translocation 
of PAR2 from the membrane to perinuclear vesicles, just as cleavage of full-length PAR2 by 
proteases. In hopes to elucidate the role of K5 in PAR2 activation, efforts were turned to a caged 
activating peptide. A peptide with the sequence S L I G PCK V was synthesized by Rajendra 
Uprety.  
First, the activating peptide (Sigma) was added to KNRK cells expressing PAR2-EGFP 
at a concentration of 100 µM (Figure 45).  The AP was added immediately after time point zero 
and ruffling of the membrane was observed between 5 and 15 minutes. Translocation of PAR2-
EGFP into perinuclear vesicles was the seen starting at 20 minutes. The response of PAR2-EGFP 
was comparable to that reported in the literature.153 
 
Figure 45: Translocation of PAR2-EGFP from the membrane to perinuclear vesicle due to treatment with the 
activating peptide (AP). Time is indicated in minutes in the top right corner.  
 
The caged AP (cAP) was added to cells that had been transfected with PAR2-EGFP 24-
hours prior to the experiment and cells were observed for 35 minutes (Figure 46). The cells were 
60  55 50  45  40  35  
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then irradiated for 10 seconds at 365 nm and watched for another 35 minutes. Unfortunately, the 
cAP induced translocation of PAR2-EGFP before irradiation. This can be seen by the ruffling of 
the membrane fluorescence, formation of a double ring and increase in perinuclear vesicle 
fluorescence 25-30 minutes after the addition of the cAP. This response is not the exact respons 
seen when the AP was added to cells expressing PAR2-EGFP, but comparable in the increase of 
fluorescence at perinuclear vesicles. Cells were irradiated in hopes that the rate of translocation 
from the membrane to perinuclear vesicles would increase. However, cells did not show a 
substantial reaction after irradiation. From these results, photochemical control of PAR2 
activation and translocation through the use of a caged lysine in the AP sequence was not 
achieved. 
 
Figure 46: Translocation of PAR2-EGFP from the membrane to perinuclear vesicle due to treatment with the caged 
activating peptide (cAP). cAP was added at time point zero. Cells were irradiated at time point 35. Time is indicated 
in minutes in the top right corner. 
 
In conclusion, photochemical control of PAR2 has not been achieved. Expression of full 
length and truncated PAR2-EGFP did show membrane-bound and perinuclear located protein, 
respectively.150 However, substitution of K5 with PCK in the tethered ligand sequence and 
expression in KNRK cells presented a mixed phenotype. Fluorescence could be seen at the 
membrane, as expected, but also in perinuclear vesicles and in the cytosol, before irradiation. 
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This could be because K5 is not a key residue in the interaction for activation and allows for 
some protein to be directed to the membrane, but not exclusively, or that the caging group is not 
large enough to block the activity of the peptide.154 Previous work has been published that 
investigated the key residues within the tethered ligand sequence. This work demonstrated that 
the first two residues of the sequence, serine and leucine, are the most important in determining 
the activation of PAR2.154 Mutation of each residue to alanine was performed and only mutation 
of Ser1 and Leu2 disrupted activation of PAR2 significantly. The work presented here agrees 
with lysine not being the most important residue in PAR2 activation. 
4.1.4 Experimental  
Generation of pPCKRS-tPAR2. pPAR2-GFP was a gift from Dr. Nigel Bunnett (UCLA).150 
Phusion PCR (Section 6.1) was performed to generate the following inserts: wtPAR2-GFP, 
tPAR2-GFP, and tPAR2-GFP K41TAG with NheI and EcoRI (compatible with MfeI on 
pPCKRS) restriction sites. Primers are listed below. 
PAR2_PCR_tWT+NheI: 5’- ACTGGCTAGCACCATGCGGAGCCCCAGCGCGGC 
PAR2_PCR_tWT+NheI: 5’- ACTGGCTAGCACCATGAGCCTTATTGGTAAGGTTG 
PAR2_PCR_tTAG+NheI: 5’- ACTGGCTAGCACCATGAGCCTTATTGGTTAGGTTG 
EGFP_PCR_WT+EcoRI: 5’- TTACGAATTCCTTACTTGTACAGCTCGTCCATGCC 
The single stranded DNA inserts were double digested as described in Section 6.2 and ligated 
into pPCKRS.  
Live-cell Imaging. KNRK cells were maintained as described in Section 6.5 and split 
into an 8-well chamber slide the day before transfection. The day of transfection DMEM was 
replaced with OptiMEM. Transfection mixtures contained 100 ng of pPCKRS-PAR2-GFP 
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variants, 100 ng of pPylT, and 0.5 µL of Lipofectamine 2000 (Life Technologies) in 50 µL of 
OptiMEM the mixture was incubated for 20 minutes at room temperature and then added to the 
cells. Cells were incubated for 4 hours at 37 ˚C/5% CO2 and then the OptiMEM was replaced 
with fresh DMEM contained 1 mM PCK if required. Cell were incubated overnight at 37 ˚C/5% 
CO2. The day of imaging DMEM was replaced with phenol red-free DMEM. Images were taken 
using a Zeiss Observer Z1 microscope with a 40X objective (NA 0.75 /EC plan-apochromat; 
Zeiss) and a GFP (38 HE) filter (ex: BP470/40; em: BP525/50). 
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5.0  OPTICAL CONTROL OF PROTEIN DIMERIZATION 
5.1.1 Introduction 
Chemical inducers of dimerization (CIDs) are small molecules that are used to bring two proteins 
of interest together. CIDs typically have two binding faces that can bind the same 
(homodimerizer) or two different (heterodimerizer) proteins of interest. Multiple CIDs have been 
developed (Figure 47) and been used in the study protein-protein interactions, signal 
transduction, gene expression and protein secretion.155  
 
Figure 47: Structures of chemical inducers of dimerization.  
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 One of the first homodimerizers developed was FK1012 (Figure 47). This is a dimer of 
FK506, which is an immunosuppressant and binds FK506 binding protein (FKBP) and 
calcineurin to impair T-cell signaling. The homodimerization of FKBP12 has been used in the 
investigation of cell proliferation,156 receptor function,157 apoptosis,158 and expansion of a 
specific subset of genetically modified cells.159 FK1012 is a FKBP homodimerizer unlike 
rapamycin, Rap, which induces formation of the ternary complex FKBP and FKBP-rapamycin 
binding (FRB) domain of the mammalian target of rapamycin (mTOR) heterodimerizer.  
A heterodimerizer that was developed from a plant hormone, gibberellin, is GA3.160 This 
small molecule dimerizes gibberellin insensitive dwarf 1 (GID1) and gibberellin insensitive 
(GAI) through a conformational change of GID1 when a gibberellin metabolite, such as GA3, is 
bound. Miyamoto and coworkers optimized GID1 and GAI to develop a CID system that is 
completely orthogonal to rapamycin. In order to increase the membrane permeability, an 
acetoxymethyl group was added to GA3 to yield the small molecule GA3-AM. This modification 
allows for the GA3-AM to cross the cellular membrane and then cellular esterases cleave the 
acetoxymethyl group to reveal the active GA3. GA3-AM was used with Rap to demonstrate the 
orthogonality of the two compounds as well as the ability to build logic gates using the two 
dimerizers. An OR gate and an AND gate were constructed using various combination of GID1, 
GAI, FKBP, and FRB. GA3-AM has since been used as rapidly control the localization of 
proteins within cells161 and to determine the diffusion barrier of cilia.162 The biggest advantage of 
this system is that it is completely orthogonal to the FKBP-rapamycin-FRB system. This allows 
for conditional control of two different proteins of interest, simultaneously. GA3-AM is also a 
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much smaller molecule than rapamycin, however, due to the negative charge that it carried at 
physiological pH, it must be modified into cross the cellular membrane.  
Another homodimerizer is coumermycin, which has two identical substituted coumarin 
rings linked together.163 This small molecule biologically inhibits the E. coli DNA gyrase and 
prevents bacterial growth, however, the binding ability has been further exploited as a chemical 
biology tool. Coumermycin specifically binds with the N-terminal domain of the DNA gyrase, 
GyrB, and does not have a eukaryotic target. This makes is especially attractive as a tool in 
eukaryotic system as it will not interfere with endogenous proteins. This homodimerizer has been 
using to investigate the signaling pathways of G-protein coupled receptors,164 Raf-1 kinase165 
and the transcription factor, Stat3.166 
One of the most extensively used heterodimerizers is rapamycin. The macrocyclic natural 
product rapamycin, Rap (Figure 47) was isolated in the 1970s and has received substantial 
attention from the scientific community due to its immunosuppressant activity.167 Naturally 
rapamycin binds to  FKBP12 with a Kd between 0.2 and 0.4 nM.168 The FKBP12-rapamycin 
complex then binds to the FRB domain (amino acids 2025-2114) of mTOR, forming a ternary 
complex consisting of the two proteins and the small molecule.167,168 This rapamycin-induced 
protein dimerization has been exploited as a research tool to control a wide range of cellular 
processes.169-171,172,173,174,175,176 FKBP12 and FRB are modular proteins that have been fused to a 
variety of protein targets to conditionally regulate them, including transcription factor 
domains,169 kinases,46 split enzyme systems such as Tobacco Etch Virus Protease (TEVp)170 and 
Cre recombinase,171  as well as cellular localization domains177 in order to allow for temporal 
control over protein function with the addition of rapamycin.   
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 Rapamycin naturally interacts with mTOR can be inhibit cell growth. To prevent the 
resulting cellular toxicity, so called “rapalogs” and FRB mutants have been developed,178 
including MaRap, BSRap, iRap, and AiRap (Figure 48). These are analogs of rapamycin with 
modifications at either the C16 or C20 position. The first rapalog was developed based on the 
observation that modification of C16 abolished FRB binding.179 Specific residues within FRB 
were mutated to create libraries that were then screened for specific binding to the rapalog. In 
addition to being less toxic than rapamycin, the rapalogs also offer the orthogonal triggering of 
two different FKBP/FRB-mutant dimerizations.  
 
 
Figure 48: Structures of MaRap, BSRap, iRap and AiRap.  
 
 Within FRB, there are three amino acids in close proximity ot C16 that have been found 
to be important in rapamycin binding: K2095, T2098, and W2101. Using a secreted alkaline 
phosphatase (SeAP) assay, the EC50 of each rapalogs was determined for multiple FRB mutants 
(Table 4). As shown, rapamycin binds with the lowest EC50 to the wild type FRB. It was found 
that a W2101F mutant allows for increased binding affinity of MaRap. However, this mutation 
greatly decreases the binding affinity of the rapalogs with modifications at C16. More 
specifically MaRap and BSRap can be used to specifically induce complex formation of their 
specific FRB mutants and FKBP because they are orthogonal to each other.  
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Table 4: EC50 values of rapalogs with FRB mutants. Reprinted from Chemistry & Biology, Bayle, J. H. et al. 
Rapamycin Analogs with Differential Binding Specificity Permit Orthogonal Control of Protein Activity. Chem Biol 
13, 99-107. Copyright 2006, with permission from Elsevier. 
 
 
 Nuclear protein import and export was used to show the orthogonality of BSRap and 
MaRap (Figure 49). An FKBP12-GSK3β-GFP fusion was designed to be used with FRBTLW-
nuclear export signal (NES) and FRBKTF-nuclear localization signal (NLS). GSK3β is a kinase 
that is typically localized in both the nucleus and the cytoplasm. By fusing it with FKBP12, the 
localization of GSK3β could be determined based on which rapalog was added to the system. 
When the proteins are coexpressed in the absence of any rapalogs, GFP fluorescence can be seen 
throughout the cells (Figure 49A). Cells that have been treated with BSRap have GFP excluded 
from the nucleus (Figure 49B). This is because BSRap interacts with FRBTLW over FRBKTF and 
causes heterodimerization of the FKBP12-GSK3β-GFP to the nuclear export signal. When 
MaRap is used, the an FKBP12-GSK3β-GFP/FRBKTF-NLS dimer is formed (Figure 49C). This 
shows that protein dimerization (and thereby protein localization) can be conditionally controlled 
based on which rapalog is added to cells and which FRB mutant is expressed.  
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Figure 49: Control of cellular localization using orthogonal rapamycin analogs. A) Localization through out the cell 
before addition of rapalog. B) Cytoplasmic localization due to binding of the nuclear export signal with the addition 
of BSRap. C) Nuclear localization after the addition of MaRap due to the binding of the nuclear import signal. 
Reprinted from Chemistry & Biology, Bayle, J. H. et al. Rapamycin Analogs with Differential Binding Specificity 
Permit Orthogonal Control of Protein Activity. Chem Biol 13, 99-107. Copyright 2006, with permission from 
Elsevier. 
 
 Woolley and co-workers developed a caged rapamycin, C7pRap (Figure 50A) to 
optically control the function of the mammalian target of rapamycin complex 1, mTORC1.180 
mTORC1 is a complex of 5 proteins, one being the mammalian target of rapamycin (mTOR) that 
activates protein synthesis through a signaling cascade that ends in the phosphorylation of S6 
ribosomal protein.181 To investigate the role of mTORC1 in protein synthesis, rapamycin can be 
used due to its ability to bind and inhibit mTOR activity. Analysis of the FKBP-rapamycin-
mTOR x-ray crystal structure showed that C-16 is positioned facing towards mTOR, thus a 
dimethoxynitrobenzyl caged group was synthetically added to rapamycin to generate 
C7pRap.168 HeLa cells were then used to determine the activity of mTORC1 by probing 
Western blots for phosphorylation of S6 (Figure 50B). Cells treated with 50 or 20 nM rapamycin 
(Figure 50B, lanes C and D) show a decrease in S6 phosphorylation due to the inhibition of 
mTORC1 by rapamycin and FKBP binding. When cells were treated with 50 or 20 nM C7pRap, 
(Figure 50B, lanes E and F) the levels of phosphorylated S6 are equivalent to those in the control 
A B C 
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or vehicle samples (lanes A and B). After a 1 minute irradiation at 365 nm, C7pRap decages to 
generate 7-hydroxy rapamycin which has been reported to have similar activity to native 
rapamycin.182 This rapamycin derivative was also shown to be active in this assay as the levels of 
phosphorylated S6 are reduced (Figure 50B, lanes G and H). This reduction in phosphorylation is 
due to the binding of 7-hydroxy rapamycin-FKBP to mTORC1 and inhibition of mTORC1 
function. This caged rapamycin was shown to optically control mTORC1 activity and 
subsequent phosphorylation of S6.  
 
 
Figure 50: Optical control of protein phosphorylation. A) Chemical structure of C7pRap. B) Phosphorylation 
analysis of S6 by Western blot. Actin was used as a load control Lanes: A: control, B: vehicle, C: 50 nM rapamycin, 
D: 20 nM rapamycin, E: 50 nM C7pRap, F: 20 nM C7pRap, G: 50 nM C7-DMNB-caged rapamycin + UV, H: 20 
nM C7pRap + UV. Reprinted from Bioorganic & Medicinal Chemistry, 18, Sadovski, O., Jaikaran, A.S.I., 
Samanta, S., Fabian, M.R., Dowling, R.J.O., Sonenberg, N., and Woolley, G.A., A Collection of Caged Compounds 
for Probing Roles of Local Translation in Neurobiology, 7746-7752, 2010, with permission from Elsevier.   
 
 In 2011, the photocleavable rapamycin-biotin conjugate cRb-A was developed.45 This 
worked off the principle that attaching HERapa to a macromolecule, such as avidin, would 
prevent HERapa from crossing the cell membrane and interacting with FRB and FKBP12, until 
fragmentation of a photocleavable linker releases HERapa from avidin, (Figure 51A). Cell 
expressing a membrane bound FRB along with a YFP-FKBP12 fusion protein exhibited YFP 
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fluorescence throughout the cell before irradiation. After irradiation and release of HERapa, 
heterodimerization and membrane localization of YFP occurred (Figure 51B).  
 
  
Figure 51: Photochemical control of protein dimerization using HERapa-avidin (cRb-A) conjugate. A) Structure of 
cRb-A and schematic of optical control. B) Membrane localization in the presence of cRb-A before and after UV 
irradiation. Adapted with permission from Umeda, N., Ueno, T., Pohlmeyer, C., Nagano, T. & Inoue, T. A 
Photocleavable Rapamycin Conjugate for Spatiotemporal Control of Small GTPase Activity. J Am Chem Soc 133, 
12-14, doi:10.1021/ja108258d|10.1021/ja108258d (2011). Copyright 2011 American Chemical Society. 
 
 To demonstrate the applicability of this caged rapamycin, the activity of Rac GTPase was 
optically controlled using localization of Tiam1. When Tiam1 is recruited to the membrane, Rac 
is activated and membrane ruffling can be seen. The membrane localized FRB was used along 
with a YFP-FKBP12-Tiam1 in NIH3T3 cells. The addition of cRb-A to the media did not induce 
membrane ruffling until a small area near the membrane was irradiated (Figure 52A). 
Importantly, Rac activation outside of the irradiated area due to diffusion of HERapa was not 
observed (Figure 52B).  
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Figure 52: Photochemical control of Rac GTPase activity using cRb-A. A) Spatial irradiation of cellular membrane 
in the presence of cRb-A. Before UV irradiation Tiam1 is not localized to the membrane, thus Rac is inactive. After 
UV irradiation and release of HERapa, Tiam1 is localized to the membrane through heterodimerization and 
membrane ruffling can be seen as a result of Rac activation. B) Spatial irradiation of cRb-A in quadrant I caused 
membrane ruffling only in that quadrant. Adapted with permission from Umeda, N., Ueno, T., Pohlmeyer, C., 
Nagano, T. & Inoue, T. A Photocleavable Rapamycin Conjugate for Spatiotemporal Control of Small GTPase 
Activity. J Am Chem Soc 133, 12-14, doi:10.1021/ja108258d|10.1021/ja108258d (2011). Copyright 2011 American 
Chemical Society. 
 
The Deiters lab reported the caged rapamycin pRap (Figure 53) in conjunction with an 
engineered FKBP domain in 2011.46 It was demonstrated that pRap had a similar activity as wild 
type rapamycin in mediating the dimerization of natural FKBP and FRB. Thus, a truncated 
mutant of FKBP12 was employed in order to improve the sensitivity of the interaction between 
pRap and FKBP. The truncation of FKBP12, termed iFKBP,183 is thought to lead to increased 
mobility of the K52–E54 loop, based on molecular dynamic simulations.46 This loop is in close 
proximity to the binding location of the caging group at C40.  
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Figure 53: Structure of photocaged-rapamycin, pRap.  
 
The caging group effectively blocked the pRap-mediated dimerization of iFKBP-FRB 
until the caging group was removed through irradiation (Figure 54A).46,183 This was used to 
optochemically control the previously designed iFKBP-FAK.183 Focal adhesion kinase (FAK) 
was inactivated by inserting a small portion of FKBP near the catalytic domain. Upon addition of 
rapamycin and heterodimerization of FRB and iFKBP, a conformational change activated FAK 
kinase. This system was used to show that pRap could be used to optochemically control FAK 
activity. Immunoprecipitation and kinase assays (Figure 54B) were also performed to show 
optochemical control of FAK activity. After UV irradiation, the heterodimization of iFKBP-FAK 
and GFP-FRB can be detected as well as the restored kinase activity of FAK through the 
phosphorylation of paxillin, a target of FAK.  
FAK activity was also photochemically control in live cells by expressing iFKBP-FAK 
and Cherry-FRB in HeLa cells (Figure 54C). When treated with pRap and before UV 
irradiation, the cell showed a normal phenotype, however, upon UV irradiation and activation of 
FAK, membrane ruffling can be seen, which is an indication that FAK has been activated due to 
the heterodimerization of iFKBP and FRB. 
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Figure 54: Application of pRap for controlling FAK. A) Schematic of photochemical control of FAK activity. B) 
Immunoprecipitation and kinase assay in the presence and absence of Rap and pRap. C) Photochemical control of 
FAK activity in live cells determined by membrane ruffling of a HeLa cell. Adapted with permission from 
Karginov, A. V. et al. Light Regulation of Protein Dimerization and Kinase Activity in Living Cells Using 
Photocaged Rapamycin and Engineered FKBP. J Am Chem Soc 133, 420-423, doi:10.1021/ja109630v (2011). 
Copyright 2011 American Chemical Society. 
 
 
5.1.2 Optical Control of Protein Dimerization Using a Rapamycin Dimer 
Since pRap is found to be still active in mediating the heterodimerization of FKBP12 and FRB, 
it was hypothesized that a larger caging group was required in order to fully abrogate its 
function. Furthermore, we speculated that an efficient way to substantially increase the size of 
the caging group is by using a second rapamycin molecule as a sterically demanding structure 
that is able to recruit an even more sterically demanding second FKBP molecule.184 Thus, the 
light-cleavable rapamycin dimer dRap was designed, in order to allow for optical control of 
wild-type FKBP12-FRB interactions, obviating the need for protein engineering of the many 
established rapamycin-controlled processes.169-176  
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 The light-cleavable rapamycin dimer dRap, (Figure 55) was synthesized from rapamycin 
in just two steps by Yan Zou (Deiters Lab). After UV irradiation, two native rapamycin 
molecules are released to participate in the binding of FRB and FKBP12.  
 
 
Figure 55: The structure the light-cleavable rapamycin dimer (dRap). 
 
Based on the crystal structure information of FRB-Rap-FKBP12 binding, it was 
hypothesized that dRap homodimerizes FKBP12 before UV irradiation. Fluorescence 
polarization was used to investigate this capability using a fluorescein isothiocyanate (FITC) 
labeled FKBP12 (Figure 56). Indeed, the addition dRap to a solution of FKBP12-FITC led to an 
increase in fluorescent polarization, indicating homodimerization of FKBP12-FITC. Moreover, 
further addition of a 10-fold excess of dRap led to a decrease in fluorescence polarization due to 
the saturation of FKBP12 binding sites with dRap molecules, effectively preventing protein 
dimer formation. Thus, it was speculate that the FKBP12-dRap-FKBP12 complex effectively 
prevents binding of FRB, until it is fragmented through photochemical cleavage of dRap. This 
hypothesis is supported by the comparison of complex formation energies calculated in 
molecular dynamics simulations.185  
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Figure 56: Fluorescence polarization of FITC labeled FKBP12 in the presence of dRap. Asterisks represent 
statistically significant differences in fluorescence polarization; P value < 0.05. Reproduced from Brown, K. A. et al. 
Light-cleavable rapamycin dimer as an optical trigger for protein dimerization. Chemical communications 51, 5702-
5705, doi:10.1039/c4cc09442e (2015) with permission from The Royal Society of Chemistry. 
 
In order to further validate dRap as an effective light-activation tool, a K-LISA mTOR 
Activity assay (Calbiochem) was performed (Figure 57A). mTOR phosphorylates the target 
protein p70S6K. However, when mTOR forms a ternary complex with FKBP12 and rapamycin, 
it cannot maintain kinase activity. Through an α–phosphorylation–HRP conjugated antibody, the 
presence of phosphorylation was monitored. As seen in Figure 57B, phosphorylation is indicated 
by high levels of luminescence in the absence of rapamycin as well as in the presence of dRap 
before UV irradation. This is due to the inability of dRap to dimerize FKBP12 and mTOR, 
allowing mTOR to retain kinase activity. Phosphorylation is reduced by nearly 80% in the 
presence of rapamycin as a result of the mTOR–Rap–FKBP12 complex formation. The decaging 
of dRap after exposure to UV light of 365 nm releases two native rapamycin molecules and 
FKBP12–mTOR heterodimerization is observed by a decrease in luminescence to the same level 
as in case of rapamycin. This shows that only upon irradiation and photolysis, but not before, 
dRap successfully dimerizes FKBP12–mTOR in vitro.   
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Figure 57: K-LISA mTOR assay of Rap and dRap. A) mTOR incubated with FKBP12 and dRap will be able to 
phosphorylate the target protein, p70S6K, due to the homodimerization of FKBP12 by dRap. UV exposure 
generates two native Rap molecules that lead to formation of the FKBP12-Rap-mTOR complex and eliminate the 
kinase activity of mTOR. B) In the absence of Rap or dRap, mTOR is functional, leading to high luminescence. 
dRap (50 nM) is blocked from inducing the heterodimerization of FKBP12 and mTOR, as shown by the high levels 
of luminescence before irradiation. Irradiation with UV light at 365 nm for 3 minutes converts dRap into Rap 
which leads to formation of the FKBP12-Rap-mTOR complex and to the same low levels of phosphorylation and 
thus luminescence as observed in the case of Rap. Reproduced from Brown, K. A. et al. Light-cleavable rapamycin 
dimer as an optical trigger for protein dimerization. Chemical communications 51, 5702-5705, 
doi:10.1039/c4cc09442e (2015) with permission from The Royal Society of Chemistry. 
 
 In order to understand why dRap does not engage in formation of a ternary complex with 
FKBP12 and FRB, a series of atomistic molecular dynamics simulations were conducted by 
David Shirvanyants from the Dokholyan lab at the University of North Carolina. Several 
different scenarios were computationally explored to explain the experimentally seen FKBP12 
homodimers instead of FKBP12-FRB heterodimers. First, it was excluded that steric hindrance 
imposed by the second rapamycin molecule may block complex formation, since it appears that 
FRB binding would be allowed in an outstretched linker conformation. Next, the binding poses 
of rapamycin and dRap to FKBP12 were examined to determine if it is possible that dRap is 
found in a position that in unfavorable for FRB binding. However, it was found that dRap 
frequently assumes FRB favorable binding positions. The final set of simulations determined the 
energies necessary for formation of the dRap mediated FKBP12 homodimer and the dRap 
mediated FKBP12-FRB heterodimer. These showed that the formation of dRap mediated 
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FKBP12 homodimers is more favorable than FKBP12-FRB heterodimers. Thus, the inability of 
dRap to heterodimerize FRB and FKBP12 is likely caused by the dominating engagement of 
dRap in the formation of FKBP12 homodimers. 
The large free energy of dRap mediated homodimerization produces highly stable 
FKBP12-dRap-FKBP12 complexes that are virtually inert to FRB, until activated by dRap 
photolysis. This tightly controlled dRap complex formation makes it well suited for light-
regulation of biological functions in live cells, as demonstrated by two important biological 
processes – protein cleavage and DNA recombination – that were investigated in tissue culture. 
Tobacco etch virus NIa protease (TEVp) is a widely used protease that recognizes a specific 
seven amino acid sequence, ENLYFQG. Cleavage occurs between the glutamine and glycine 
residues, and this recognition sequence has been genetically engineered into various proteins to 
either activate or deactivate their function.170 TEVp has been used to intracellularly cleave 
proteins from purification tags,186 to cleave stabilization proteins from bioactive 
glycopeptides,187 to aid in the discovery of protein-protein interactions,188 and in the inactivation 
of proteins in vivo.189 Conditional control of TEVp activity was achieved through the application 
of an inducible TEV expression system186 and the development of a split TEVp system.170 In 
latter case, TEVp was divided into N- (amino acids 1-118) and C- (amino acids 119-241) 
terminal fragments and each fragment was fused to FRB and FKBP12, respectively. Co-
expression of both fusion proteins did not display any protease activity until the addition of 
rapamycin, which induces dimerization and restores activity of TEVp.  
To investigate the photochemical control of protease activity (Figure 58A), dRap was 
tested in HEK293T cells expressing the FKBP12-TEV C-terminus and the FRB-TEV N-
terminus,170 as well as a circularly permuted luciferase reporter containing a TEVp cleavage site 
 92 
(GloSensor, Promega).190 Active TEVp will cleave the GloSensor protein, causing a 
conformational change that leads to an activation of the luciferase reporter and luminescence. As 
seen in (Figure 58B) addition of wild-type rapamycin to the transfected cells led to the 
generation of a luminescence signal, while in the absence of rapamycin only a very low 
background level of luminescence was detected. Importantly, only background luminescence 
was observed when the light-cleavable rapamycin dimer dRap was added to the media in the 
absence of UV irradiation. This demonstrates the inability of dRap to heterodimerize FRB and 
FKBP12. Upon a 5-minute irradiation with UV light of 365 nm, the luminescence signal is 
restored to the same level as rapamycin induction. Thus, irradiation efficiently cleaves the light-
sensitive linker, releasing two active rapamycin molecules from one dRap molecule. The 
released rapamycin stimulates dimerization of FBKP12 and FRB, leading to TEVp activity. 
Importantly, in addition to being fully inactive in vitro, the rapamycin dimer is also fully inactive 
in tissue culture and a brief UV irradiation restores TEVp activity to the same level as the 
addition of rapamycin itself. 
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Figure 58: A) Representative schematic of the photochemical activation of split TEV using dRap. FKBP12-TEV 
C-terminus (blue) and FRB-TEV N-terminus (red) dimerize only after irradiation of dRap and release of two native 
rapamycin molecules. Active TEVp then cleaves the TEVp recognition site of a circularly permutated luciferase 
protein, inducing catalytic activity and thus luminescence. B) Luminescence data from the split TEVp/GloSensor 
assay using dRap. HEK293T cells expressing FKBP12-TEV C-terminus, FRB-TEV N-terminus, and the GloSensor 
reporter were treated with rapamycin (100 nM) or dRap (50 nM) and irradiated for 5 minutes at 365 nm. 
Luminescence readings were taken 24 hours after irradiation.  Reproduced from Brown, K. A. et al. Light-cleavable 
rapamycin dimer as an optical trigger for protein dimerization. Chemical communications 51, 5702-5705, 
doi:10.1039/c4cc09442e (2015) with permission from The Royal Society of Chemistry. 
 
Light-activation of dRap, and thus photochemical control of TEVp, allows for non-
invasive activation of site-specific protein cleavage in live cells. In addition to protein 
manipulation, the application of the light-activated rapamycin dimer was also investigated in the 
manipulation of DNA, specifically DNA recombination by Jie Zhang of the Deiters Lab. In this 
context, Cre recombinase is an important tool in cell and developmental biology, as it recognizes 
two palindromic sequences of DNA, known as loxP sites, and is able to delete, insert, or invert 
any DNA sequence that is located between those sites, depending on their orientation.171 Cre-
catalyzed DNA recombination has been extensively used for a wide range of applications 
starting from simple DNA recombination in E. coli,191 to genetic engineering in yeast,192 
plants193 and mice.194 Genetic engineering in mice is widely applied and has allowed for the 
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conditional control of genes by a loxP flanked stop region195 as well as specific chromosomal 
rearrangements to mimic human diseases.196 One of the limitations of Cre is the inability to 
tightly control the recombination process with external regulatory elements. Methodologies have 
been developed for the spatiotemporal control of Cre recombinase, including the regulation of 
Cre catalysis with a photocaged tamoxifen,197 by caging the catalytic tyrosine residue within the 
active site,198 and by fusing each fragment of a split Cre enzyme to a blue light-absorbing 
photoreceptor and its binding partner.39 However, there are limitations to each of the current 
methodologies. When using photocaged tamoxifen there is need for multiple irradiations and 
limited restoration of Cre activity is seen.197 There is a requirement of continuous pulses of light 
for 24 hours when using the split-Cre fused to a natural photoreceptor,39 and in case of the 
active-site caged Cre recombinase genetic encoding in mammalian cells has not been 
achieved.198  
Here, we are reporting a solution to these problems by utilizing a split Cre system 
composed of amino acids 19-59 (N-terminus) and amino acids 60-343 (C-terminus) that was 
fused to FKBP12 and FRB,171 respectively, enabling the photochemical control of Cre-catalyzed 
DNA recombination by dRap (Figure 59).  
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Figure 59: Representative schematic of the split Cre system using dRap. A) FRB-Cre C-terminus (red) and 
FKBP12-Cre N-terminus (blue) are dimerized after irradiation of dRap. B) The Cre stoplight reporter expresses 
dsRed before irradiation, but in the presence of reconstituted, active Cre, the dsRed gene is excised and EGFP is 
expressed.  Reproduced from Brown, K. A. et al. Light-cleavable rapamycin dimer as an optical trigger for protein 
dimerization. Chemical communications 51, 5702-5705, doi:10.1039/c4cc09442e (2015) with permission from The 
Royal Society of Chemistry. 
 
To examine the ability of dRap to photochemically control Cre catalyzed DNA 
recombination, HEK293T cells expressing a split Cre system and the Cre Stoplight reporter were 
used, Figure 60. The Cre Stoplight plasmid expresses DsRed when Cre recombinase is absent or 
non-functional. In the presence of active Cre, the gene coding for dsRed is excised from the 
plasmid due to flanking loxP sites and CMV-driven EGFP expression is activated.199 In the 
presence of dRap but the absence of UV irradiation, only dsRed is expressed, an indicator that 
dRap is not capable of heterodimerizing FKBP12 and FRB leading to an inactive Cre 
recombinase (as seen by red fluorescence present in Figure 60A). This is in perfect agreement 
with the results obtained from cells that are not treated with rapamycin. DNA recombinase is 
active through the decaging of dRap with a brief 5-minute irradiation at 365 nm producing two 
native rapamycin molecules to participate in the FKBP12-00-FRB ternary complex and thus 
complementation of Cre fragments. The reconstituted Cre enzyme excises the dsRed gene and 
induces EGFP expression (Figure 59). Quantification of the micrographs using the Zen 2009 
software further confirms these results (Figure 60B).  
 
 
active Cre inactive, split Cre 
+ 
loxP - UV loxP dsRed EGFP 
stop 
CMV 
+ UV loxP dsRed loxP EGFP + 
stop 
CMV 
A B 
 96 
  
Figure 60: Light-activated Cre DNA recombination. Plasmids encoding each fragment of the split Cre enzyme and 
the Cre stoplight reporter were transfected into HEK293T cells. A) Cells were treated with rapamycin (5 nM) or 
dRap (10 nM) and imaged for fluorescence. B) Micrographs were quantified by integrating randomly selected areas 
using Zen imaging software. Error bars are standard deviations generated from three independent integrations. 
Reproduced from Brown, K. A. et al. Light-cleavable rapamycin dimer as an optical trigger for protein dimerization. 
Chemical communications 51, 5702-5705, doi:10.1039/c4cc09442e (2015) with permission from The Royal Society 
of Chemistry. 
 
The synthetic strategy developed above was also applied to generate other dRap analogs, 
containing shorter, more rigid, and photoswitchable linkers (Figure 61). The dRap-II and dRap-
III analogs were thought to further reduce background due to their rigidity. The photoswitchable 
dRap-IV may provide reversible control of FKB/FRBP12 dimerization, an important goal, since 
no good method exists to break the FRB-Rap-FKBP12 complex once it has formed.  
- UV + UV 
EGFP DsRed EGFP DsRed 
– Rap 
+ Rap 
+ dRap 
0% 
20% 
40% 
60% 
80% 
100% 
120% 
140% 
pe
rc
en
t f
lu
or
es
ce
nc
e 
GFP 
DsRed 
Rap 
dRap 
– 
– 
+ 
– 
– 
+ 
UV 
– 
+ 
– – – + 
A B 
 97 
  
Figure 61: Structure of dRap analogs 
 
In order to quickly and efficiently investigate the dimerizer functions of the new dRap 
analogs, a fluorescence protein membrane localization system was used (Figure 62A).124 Cells 
are transfected with two plasmids: pLyn-FKBP12x2-CFP and pFRB-YFP. The first plasmid 
expresses a CFP reporter fused to two FKBP12 proteins and anchored in the cell membrane 
through an N-terminal Lyn domain. The second plasmid expresses a cytosolic YFP-FRBKLW 
fusion protein. The FRBKLW mutant undergoes dimerization with FKBP in the presence of iRap 
or Rap that leads to translocation of YFP to the cell membrane (Figure 62B).  
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Figure 62: Membrane localization system for determination of heterodimerization properties of dRap analogs. A) 
Schematic of proteins in membrane localization system. B) Localization of YFP to the membrane upon addition of 
iRap. Reprinted by permission from Macmillan Publishers Ltd: Nature Methods. Inoue, T., Heo, W. D., Grimley, J. 
S., Wandless, T. J. & Meyer, T. An inducible translocation strategy to rapidly activate and inhibit small GTPase 
signaling pathways. Nat Methods 2, 415-418, doi:10.1038/nmeth763 (2005)., copyright 2005.  
 
 
It was first determined if the dRap analogs induced translocation before irradiation. Cells 
expressing Lyn-FKBP12x2-CFP and FRB-YFP were imaged overnight in the presence of the 
analogs (Figure 63). Importantly, dRap-II and dRap-IV did not induce translocation (Figure 
63A and C). Unfortunately, dRap-III heterodimerized FKBP12 and FRB at a rate similar to Rap 
causing YFP translocation to the membrane (Figure 63B). It is unknown as to why this analog 
functions as a CID before UV irradiation, since the photocleavable linker is approximately the 
same length as the other linkers.  
 
A B 
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Figure 63: Membrane localization of YFP using dRap analogs. HeLa cells were expressing Lyn-FKBP12x2-CFP 
and FRB-YFP. Time is indicated in minutes in the upper right corner. A) HeLa cells treated with 100 nM dRap-II 
overnight. Membrane localization was not seen. B) HeLa cells treated with 100 nM dRap-III overnight. Membrane 
localization was seen slightly after 5 minutes and significantly after 80 minutes. C) HeLa cells treated with 100 nM 
dRap-IV overnight. Membrane localization was not seen. Images were taken on a Nikon A1 confocal microscope 
with a 20X objective using a 488 nm laser and detectors were set to collect emission from 505 nm to 585 nm.  
 
TIRF microscopy was then used to quantitatively trace the YFP membrane fluorescence 
before and after irradiation. As seen in Figure 64, addition of rapamycin caused an exponential 
increase in membrane fluorescence over a short period of time, followed by a plateau. The same 
pattern was observed when dRap-III was added to cells. When dRap or dRap-II was added to 
cells, a small increase in fluorescence was seen. Unfortunately, after UV irradiation, a steep drop 
off in fluorescence was seen. dRap-IV induced some translocation without irradiation, which 
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was not seen in the confocal images.  The steep drop in fluorescence after UV irradiation is 
hypothesized to be due to photobleaching of YFP during the irradiation. This problem has not 
been solved.  
  
Figure 64: Increase in membrane fluorescence measured through TIRF microscopy. Rap, dRap-III or dRap was 
added to HeLa cells expressing Lyn-FKBP12x2-CFP and FRB-YFP at the indicated time and the membrane 
fluorescence was imaged over time. Cells with dRap were irradiated at the indicated time.  
 
In conclusion, a light-cleavable rapamycin dimer (dRap) was developed that does not 
induce FKBP12 and FRB heterodimerization until it is activated through UV exposure. Light 
irradiation cleaves the dimer and delivers two native rapamycin molecules that mediate 
formation of the FKBP12-rapamycin-FRB ternary complex. Previously reported, caged 
-0.2 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
-5 -10 0 5 10 15 20 25 30 35 40 45 50 
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 
Time (min) 
Rap 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
-5 -10 0 5 10 15 20 25 30 35 40 45 50 
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 
Time (min) 
dRap-III 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
-5 -10 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 
Time (min) 
dRap UV 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
-1
5 
-1
0 -5
 0 5 10
 
15
 
20
 
25
 
30
 
35
 
40
 
45
 
50
 
55
 
60
 
65
 
70
 
75
 
80
 
85
 
90
 
95
 
10
0 
10
5 
R
el
al
tiv
e 
Fl
uo
re
sc
en
ce
 
Time (min) 
dRap-II 
UV 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
-1
5 
-1
0 -5
 0 5 10
 
15
 
20
 
25
 
30
 
35
 
40
 
45
 
50
 
55
 
60
 
65
 
70
 
75
 
80
 
85
 
90
 
95
 
10
0 
10
5 
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 
Time (min) 
dRap-IV 
 101 
rapamycin analogs have been applied to photochemically control protein phosphorylation;45,46, 180 
however, these methodologies have substantial limitations. They require protein engineering of 
the FKBP domain or mislocalization of the rapamycin molecule outside of the cell, since the 
presence of the synthetic caging groups alone did not prevent rapamycin-induced FKBP12-FRB 
dimerization. Thus, the caged rapamycin analogs could not be directly interfaced with the wide 
range of biological processes that have been placed under conditional control through the 
construction of FKBP12-rapamycin-FRB based biological switches in cells and multicellular 
organisms. The rapamycin dimer (dRap) was envisioned as an optochemical approach that 
utilizes recruitment of an entire protein184 in order to dramatically increase the steric hindrance 
imposed by the caging group installed at position C-40 of rapamycin. Moreover, the design was 
kept as simple as possible and utilized a naturally occurring, endogenous protein for this purpose. 
Thus, the light-cleavable rapamycin dimer dRap was synthesized and evaluated for its ability to 
form the ternary FKBP12-dRap-FRB complex before and after light irradiation. Most 
importantly, it was found that dRap was completely inactive as a heterodimerizer. In order to 
investigate the molecular mechanism behind this inactivity, molecular dynamics simulations 
were performed and it was discovered, by eliminating all other possibilities, that indeed 
recruitment of a second FKBP12 protein to FKBP12-dRap efficiently prevents interaction with 
FRB. Fluorescence polarization measurements support the molecular dynamics simulations. This 
represents the first example of intracellular formation of a highly sterically demanding caging 
group through the recruitment of an endogenous protein and can be used to photochemically 
control processes that require more steric bulk than offered by traditional caging groups to block 
small molecule function. UV exposure switches the FKBP12-dRap-FKBP12 complex to the 
FKBP12-Rap-FRB complex, and it was demonstrated that TEV protease activity and Cre DNA 
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recombinase activity can be optochemically controlled in living cells using this methodology. 
Because of the modularity of FRB and FKBP12, dRap has implications in the light-regulation of 
protein dimerization and protein activity in a wide range of biological processes that have 
already been rendered responsive to rapamycin, but could not be readily placed under 
optochemical control until now.46,172-176  
Furthermore, the same synthetic approach that was used for dRap was used to develop 
three more analogs: two photocleavable analogs and a photoswitchable analog. dRap-II and 
dRap-IV did not induce translocation of YFP to the membrane before UV irradiation. Addition 
of dRap-III to the media triggers translocation of YFP to the membrane without UV irradiation. 
This is undesirable and dRap-III cannot be used of optical control of FKBP12 and FRB 
heterodimerization. Currently, work is progressing towards the ability to image membrane 
fluorescence after UV irradiation.  
5.1.3 Experimental  
Fluorescence Polarization Assay. FKBP12 (R&D Systems) was stirred with fluorescein 
isothiocyanate (FITC) at a 1:5 ratio for 3 hours in carbonate-bicarbonate buffer (pH 9.0). 
FKBP12-FITC was separated from free FITC by overnight dialysis (MWCO 3,500 Da; Spectrum 
Laboratories, Inc.) into phosphate buffered saline (PBS; pH 7.4). Protein was recovered and the 
concentration was determined by measuring absorbance on a NanoDrop ND-1000 
spectrophotometer using the literature value for the molar extinction coefficient of FITC.200 
FKBP12-FITC was diluted to 2 µM and dRap was dissolved at a 100X the final concentration in 
PBS. FKBP12-FITC was aliquoted into a 384-well plate and dRap 100X stocks were added 
resulting in the required final concentrations of 200 nM, 2 µM, or 20 µM. After 20 minutes of 
 103 
incubation at room temperature, fluorescence polarization was measured on a Biotek Synergy 4 
microplate reader. 
K-LISA mTOR Activity Assay. GST-p70S6K (Calbiochem) was incubated in 
glutathione coated plates for 1 hour. mTOR (Sigma-Aldrich) was mixed with FKBP12 (R&D 
Systems) and either rapamycin (100 nM) or dRap (50 nM). Samples were placed in the dark or 
irradiated with UV light for 3 minutes on a transillumintor (365 nm, 25 W) and then kept on ice 
for 20 minutes. The samples were added to GST-p70S6K containing wells and incubated at 30 
˚C for 30 minutes. p70S6K phosphorylation was detected with an α-p70S6K-T389 
phosphorylation antibody and Luminata Forte ELISA HRP Substrate (Millipore) on a Biotek 
Synergy 4 microplate reader. 
TEVp Complementation Assay. HEK-293T cells were maintained at 37 °C and 5% 
CO2 in Dulbecco’s modified Eagle’s medium (Hyclone) supplemented with 10% fetal bovine 
serum (Hyclone) and 10% streptomycin/penicillin (MP Biomedicals). Cells were passaged into a 
96-well plate and when 80-90% confluent, were transfected with pFRB-TEVnt, pFKBP12-
TEVct, and pTriExGloSensor (100 ng/each) using Lipofectamine 2000 (0.5 µL) (Invitrogen) 
according to manufacturer’s protocol.  Twenty-four hours after transfection rapamycin (100 nM) 
or dRap (50 nM) were added and cells were incubated for 3 hours at 37 °C and 5% CO2. 
Luciferase activity was determined using a Bright Glo-Luciferase Reporter Assay kit (Promega) 
and a Biotek Synergy 4 microplate reader.  
Cre Recombinase Complementation Assay. HEK-293T cells were passaged into two 4-
well chamber slides, and grown to 80% confluency. The cells were then transfected with the Cre 
Stoplight (600 ng, 1 well per slide), pcDNA-FKBP-Cre59 (60 ng, 1 well per slide) and pcDNA-
FRB-Cre60 (60 ng, 1 well per slide) using X-tremeGENE HP DNA transfection reagent (2:1 X-
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tremeGENE/DNA; Roche Biomedicals) in OptiMEM medium (Invitrogen). The transfection 
mixture was incubated at 37 °C for 6 hours, followed by the replacement of the OptiMEM 
transfection medium with DMEM. The cells were then incubated with rapamycin (10 nM) or 
dRap (5 nM) at 37 °C and 5% CO2 overnight, followed by irradiation of selected wells for 5 min 
on a transilluminator   (365 nm, 25 W) and replacement of medium with DMEM grow medium. 
Thirty-six hours post transfection, the cells were analyzed on a Carl Zeiss LSM 700 laser 
confocal microscope with a 20X plan-apochromat objective for the expression of GFP 
(excitation at 488 nm with an argon laser and emission at 493-545 nm) and DsRed (excitation at 
561 nm with a solid state laser and emission at 574-659 nm) reporter proteins. Quantification of 
fluorescence was performed using Zen 2009 imaging software. Three independent integrations 
were performed. 
Membrane Localization Live-Cell Imaging. HeLa cells were seeded in an 8-well 
chamber slide according to Section 6.5 and transfected according to Section 6.6. The day of 
imaging media was removed and replaced with DMEM without phenol red. Cells were placed in 
a stage top incubator (Tokai Hit) at 37 °C with 5% CO2. Cells were imaged using a Nikon A1 
confocal microscope using the lasers indicated in the caption.  
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6.0  GENERAL PROTOCOLS 
6.1 PHUSION PCR 
 
Combine all components of the reaction mixture (see below), adding Phusion polymerase (NEB) 
last, and mix thoroughly. Place reaction tubes in a thermocycler and program according to the 
temperatures and times in Table 5.201 The temperature for the annealing step should be calculated 
based on the specific primers for insert amplification. The extension time should be calculated 
back on the length of the insert. After the program has been executed, add 11.1 µL of CutSmart 
buffer (NEB) and 1.1 µL of DpnI (NEB) to the reaction and incubate for 1 hour at 37 ˚C. Purify 
the DNA insert using a PCR purification kit (Qiagen or Omega Bio-Tek) and elute in 50 µL of 
warm (~42 ˚C) water.    
    Table 5: Thermocycler program for Phusion PCR 
Reaction Mixture (100 µL) 
20 µL of 5X Phusion buffer 
2 µL of dNTPs 
5 µL of Primer A (10 µM stock) 
5 µL of Primer B (10 µM stock) 
1 µL of Template DNA 
1 µL of Phusion polymerase 
66 µL of water 
 
 
 
 
Temperature Time # of cycles 
95 ˚C 30 sec. 1 
95 ˚C 10 sec. 
30 
Primer Tm – 5˚C 30 sec. 
72 ˚C 30 sec. 
per  
1000 
bp 
72 ˚C 10 
min. 
1 
12 ˚C hold  
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6.2 DNA DIGESTION AND LIGATION 
For single or double digestion of PCR products or up to 4 µg of backbone, mix DNA (up to 44 
µL) with 5 µL of the appropriate 10X buffer from NEB, 0.5 µL of the enzyme(s), and the 
appropriate volume of water to make a 50 µL final volume. Incubate the reaction at 37 ˚C for 2 
hours and then heat inactivate enzymes by incubating at 75 ˚C for 20 minutes.  
DNA backbones were treated with Antarctic Phosphatase (AP) after digestion by adding 
5.5 µL of 10X AP buffer, and 0.55 µL of AP to the 50 µL of heat-inactivated digestion reaction. 
This reaction was incubated at 37 ˚C for 1 hour and then gel purified with a Gel Extraction kit 
(Omgea).  
To ligate DNA inserts into DNA backbones, the appropriate volumes were calculated 
using the equation below. Solving for X produced the ratio to determine the volumes of backbone 
and insert that were used in the ligation reaction. The ligation reaction mixture was 1 µL of 10X 
ligase buffer, 0.2 µL of ligase and the predetermined ratio of insert and backbone to equal up to 
8.8 µL. If the volumes of insert and backbone do not equal 8.8 µL exactly, water was used to fill 
the reaction to 10 µL. The reaction was incubated at 4 ˚C overnight and transformed into bacteria 
the following day.  !"#$%#&'(&)"#  !"  !"!"#$%&  (!" µμ!)  ×  1!"#$%&  !"  !"#$%"&'#  !"  !"#$!%&'   ×  10   =   !"#$%#&'(&)"#  !"  !"#$%&  (!" µμ!)  ×  !!"#$%&  !"  !"#$%"&'#  !"  !"#$%&  
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6.3 SITE-DIRECTED MUTAGENESIS 
Primers for site-directed mutagenesis (SDM) were designed according to the diagram 
below and the following restrictions: (1) Tm(no) = Tm(pp) + 5-10 ˚C, (2) Tm (forward) ≅ Tm 
(reverse), (3) ΔG of 3’ hairpins < –2.5.  
 
Figure 65: Schematic for designing site-directed mutatgenesis primers. 
 
The reaction mixture was combined and Phusion polyermase (NEB) was added last The 
reaction was mixed thoroughly and placed in thermocycler and program according to the 
temperatures and times below.202,203 After the program has been executed, add 3 µL of CutSmart 
buffer (NEB) and 0.3 µL of DpnI (NEB) to the reaction and incubate for 1 hour at 37 ˚C. DNA 
was then transformed according to the procedure below.  
     Table 6: Thermocycler program for site-directed mutagenesis.  
 
 
Reaction Mixture (100 µL) 
5 µL of 5X Phusion buffer 
1 µL of dNTPs 
2.5 µL of Primer A (10 µM stock) 
2.5 µL of Primer B (10 µM stock) 
1 µL of Template DNA (5 ng/µL stock) 
1 µL of Phusion polymerase 
12 µL of water 
 
 
mutation 
pp no 
no 
forward reverse 
Temperature Time # of 
cycles 
95 ˚C 5 min. 1 
95 ˚C 1 min. 
15 
Tm (whole) – 5˚C 1 min. 
72 ˚C 1 min. 
per  
500 bp 
Tm (pp) – 5 ˚C 1 min 1 
72 ˚C 30 min. 1 
12 ˚C hold  
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6.4 TRANSFORMATION 
Thaw competent cell vial, typically 50 µL, on ice. Add 1 µL DNA for general amplification of 
plasmids and 10 µL of ligations of SDM reactions. Incubate on ice for 30 minutes. Heat shock in 
a 42 ˚C water bath for 45 seconds. Incubate on ice for 2 minutes. Add 500 µL SOC to each 
transformation and shake at 37 ˚C for 1 hour. Plate 100 µL on LB agar containing the 
appropriate antibiotic for general plasmid amplification and plate all of the transformation for 
ligations and SDM reactions. Incubate plates overnight at 37 ˚C upside down.  
6.5 CELL CULTURE MAINTENANCE  
Incubate mammalian cells at 37 ˚C/5% CO2 in 10 cm plates with 10 mL of DMEM. Every two to 
three days passage the cells for continued growth by removing the media, adding 1 mL of 
TrypLE (Gibco) and incubating for 5-10 minutes. Passaging schedule depends on the growth rate 
of the cells. Cells were checked every day for confluency to ensure they did not overgrow. 
Typically HEK293T cells and HeLa cells were passaged every two days. Detach the cells from 
the plate by pippetting the solution over them with a 1000 µL pipet. Add 9 mL of fresh pre-
warmed DMEM to the detached cells and mix gently by swirling the plate. For continued cell 
growth, add 1 mL of the newly resuspended cells to 9 mL of fresh DMEM. These plates should 
be labeled with cell type, passage number, date and initials, and incubated at 37 ˚C/5% CO2 until 
the next passage is required. The cells remaining in the plate will be passaged into plates or 
chamber-slides for experiments if necessary. The volumes of cell-suspension and fresh DMEM 
for various plate sizes can be found below.  
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Table 7: Seeding volumes for vary sized plates.  
Plate Type Volume of Cell-
Suspension 
Volume of Fresh 
DMEM 
Total Volume 
8-well chamber slide 100 µL 200 µL 300 µL 
96-well plate 50 µL 150 µL 200 µL 
6-well plate 750 µL 1.25 mL 2 mL 
 
6.6 TRANSFECTION 
On the day of transfection, replace the DMEM with fresh media without antibiotics. Place plate 
with cells in incubator (37 ˚C/5% CO2) while the transfection mixture is prepared. Combine 
OptiMEM, DNA, and LPEI according to the table below. Mix well and incubate for 10 minutes 
at room temperature. Add the transfection mixture to the appropriate wells and incubate 
overnight at 37 ˚C/5% CO2.  
Table 8: Transfection volumes for LPEI transfection in varying plate sizes. 
Plate Type Volume of DMEM 
without antibiotics 
Volume of 
OptiMEM 
Volume of 
LPEI 
Amount of 
total DNA 
8-well chamber 
slide 
180 µL 20 µL 2 µL 200 ng 
96-well plate 180 µL 20 µL 2 µL 200 ng 
6-well plate 1.8 mL 200 µL 20 µL 2 µg 
 
6.7 MAMMALIAN CELL LYSIS 
Remove DMEM with the transfection mix and wash cells with 1 mL of cold PBS. Add 200 µL 
of appropriate lysis buffer directly to each well, place the plate on ice and rock for 20 minutes. 
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Transfer the lysates to microcentrifuge tubes and centrifuge at maximum speed (21,130 × g) for 
20 minutes at 4 °C. Transfer supernatants to new microcentrifuge tubes and discard the debris 
pellets.  
6.8 SDS-PAGE 
Add 30 µL of supernatant to 10 µL of 4× SDS loading dye and mix by pipetting. Heat for 5 
minutes at 95 °C. Load 15 µL of the protein solution from each well into 2 lanes of a 10-well 
SDS-PAGE gel. Two lanes are loaded in order to blot for the protein of interest and the GAPDH 
control in the Western blot protocol. Run gel at 60 V for 15 minutes and 150 V for 45 minutes to 
1 hour until the dye front has run off the gel.  
6.9 WESTERN BLOTTING 
To transfer proteins from the gel to the PVDF membrane (GE Healthcare) using a Bio-Rad wet 
transfer system, start with the black side of the transfer cassette down in a dish with enough cold 
transfer buffer to cover the transfer cassette, stack the foam pad, 2 sheets of filter paper, and the 
SDS-PAGE gel. Soak the PVDF membrane in 15 mL of methanol for 1 minute and place it on 
top of the gel. Carefully remove any air bubbles from between the gel and the membrane. Add 2 
sheets of filter paper and another foam pad on top of the membrane and close the transfer 
cassette. Place the transfer sandwich in the transfer apparatus and then into a gel tank that is 
filled with ice-cold transfer buffer. Add an ice pack to the tank and run the transfer at 80 V for 1 
 111 
hour.  Alternatively, the tank can be placed into an ice bath during transfer. Remove the 
membrane from the transfer sandwich and place it protein-side up in a suitable container (e.g., a 
50 mL Falcon tube). The rest of the transfer sandwich can be discarded. Block the membrane 
with 25 mL of 2.5% milk in TBST for 1 hour while rocking at room temperature. Incubate the 
membrane with the appropriate antibody overnight at 4 °C while rocking. Antibody dilutions are 
typically 1:1000 in 15 mL TBST with 2.5% milk. Wash the membrane three times with 15 mL of 
TBST for 5 minutes each. Incubate the membrane with 15 mL of goat anti-rabbit-HRP conjugate 
antibody (1:30,000 dilution in TBST) for 1 hour while rocking at room temperature. Wash the 
membrane three times with 15 mL of TBST for 5 minutes each. Develop the membrane using the 
VisiGlo Prime HRP Chemiluminescent Substrate Kit (Amresco). Image the chemiluminescence 
signal using a ChemiDoc gel imaging system (Bio-Rad). Signal should be accumulated for 30 
seconds using the chemiluminescent setting, “Chemi.” If this does not result in a clear image of 
the Western blot bands, accumulation time can be increased. Alternative, if the signal is too high, 
the accumulation time can be decreased. 
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APPENDIX A 
Reagent recipes 
10X Phosphate buffered saline (PBS) (250 mL) 
 20 g of sodium chloride 
 0.5 g of potassium chloride 
 3.6 g of sodium phosphate (dibasic) 
 0.6 g of potassium phosphate (monobasic) 
  
Fill to 250 mL with MilliQ water. Adjust the pH to 7.4 +/– 0.2. Sterilize by autoclaving 
and store at room temperature of 4 ˚C. Dilute to 1X before use.  
 
10X Tris buffered saline (TBS) (1 L) 
 87.6 g of sodium chloride 
 12.1 g of Tris-base 
  
Fill to 900 mL with MilliQ water and adjust the pH to 7.6 +/– 0.2. This will take 
approximate 15 mL of 60% hydrochloric acid. Then fill to 1 L with MilliQ water. Store at room 
temperature.  
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Tris buffered saline with Tween-20 (TBST, 500 mL) 
 50 mL of 10X TBS 
 0.5 g of Tween-20 
  
 Add 450 mL of MilliQ water and mix thoroughly.  
 
10X Western blot transfer buffer (1 L) 
 30.3 g of Tris-base 
 144 g of glycine 
  
 Fill to 1 L with MilliQ water and mix thoroughly. Store at 4 ˚C.  
 
Western blot transfer buffer (2 L) 
 200 mL of 10X Western blot transfer buffer 
 400 mL of methanol  
 0.5 g of sodium dodecyl sulfate 
 
Fill to 2 L with MilliQ water and mix thoroughly. Store at 4 ˚C. Western blot transfer 
buffer can be reused three times.  
 
10X SDS-PAGE running buffer (1 L)  
 30 g of Tris-base 
 144 g of glycine 
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 10 g of sodium dodecylsulfate 
 
Fill to 1 L with MilliQ water and mix thoroughly. Store at room temperature. Dilute to 
1X before use. Diluted SDS-PAGE running buffer can be reused up to 5 times.  
 
Western blot stripping buffer 
 2% sodium dodecylsulfate (SDS) 
 100  mM β-mercaptoethanol (BME) 
 50 mM Tris, pH 6.8 
  
 
4% SDS-PAGE stacking gel (2 mL) 
 1.458 mL of water 
 0.25 mL of 40% acrylamine 
 0.25 mL of 1 M Tris, pH 6.8 
 20 µL of 10% sodium dodecylsulfate (SDS) 
 20 µL of 10% ammonium persulfate (APS) 
 2 µL of Tetramethylethylenediamine (TEMED) 
 
 
8% SDS-PAGE gel (5 mL) 
2.645 mL of water 
 1 mL of 40% acrylamine 
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 1.25 mL of 1 M Tris, pH 6.8 
 50 µL of 10% sodium dodecylsulfate (SDS) 
 50 µL of 10% ammonium persulfate (APS) 
 5 µL of Tetramethylethylenediamine (TEMED) 
 
 
10% SDS-PAGE gel (5 mL) 
 2.4 mL of water 
 1.25 mL of 40% acrylamide 
 1.25 mL of 1.5 M Tris, pH 8.9 
 50 µL of 10% sodium dodecylsulfate (SDS) 
 50 µL of 10% ammonium persulfate (APS) 
 3 µL of Tetramethylethylenediamine (TEMED) 
 
12% SDS-PAGE gel (5 mL) 
 2.15 mL of water 
 1.5 mL of 40% acrylamide 
 1.25 mL of 1.5 M Tris, pH 8.9 
 50 µL of 10% sodium dodecylsulfate (SDS) 
 50 µL of 10% ammonium persulfate (APS) 
 3 µL of Tetramethylethylenediamine (TEMED) 
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15% SDS-PAGE gel (5 mL) 
 1.775 mL of water 
 1.875 mL of 40% acrylamide 
 1.25 mL of 1.5 M Tris, pH 8.9 
 50 µL of 10% sodium dodecylsulfate (SDS) 
 50 µL of 10% ammonium persulfate (APS) 
 3 µL of Tetramethylethylenediamine (TEMED) 
 
 
DMEM 
 5.89 g of DMEM powder 
 1.63 g of sodium bicarbonate 
 0.145 g of L-glutamine 
  
Add 440 mL of MilliQ water and pH to 7.4 ± 0.2. Add 50 mL fetal bovine serum and 10 
mL of penicillin/streptomycin in the biological safety cabinet. Filter media and store at 4 ˚C for 
up to two months. Before use, media should be warmed at room temperature for 30 minutes or in 
a 37 ˚C water bath until warm.  
 
Kinase lysis buffer 
 20 mM Tris 
 10% glycerol 
 1% Triton-X100 
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 200 mM sodium chloride 
 25 mM β-glycerophosphate 
 2 mM ethylenediaminetetraacetic acid (EDTA) 
 0.5 mM dithiothreitol (DTT) 
 1 mM sodium orthovanadate 
 2 mM sodium pyrophosphate 
 1 mM phenylmethanesulfonylfluoride (PMSF) 
 50 mM sodium fluoride 
 protease inhibitor (diluted to manufacturer’s instructions) 
 
 Make fresh before use and keep on ice.  
 
Phosphorylation lysis buffer (from Haugh Lab) 
 50 mM HEPES, pH 7.4  
 100 mM sodium chloride 
 10% (w/v) glycerol 
 1% (v/v) Triton X-100 
 1 mM sodium orthovanadate 
 50 mM β-glycerophosphate, pH 7.3 
 5 mM sodium fluoride  
 1 mM ethylene glycol tetraacetic acid 
 10 mM sodium pyrophosphate, pH 7.0 
 protease inhibitor (diluted to manufacturer’s instructions) 
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 Make fresh before use and keep on ice.  
 
Kinase assay buffer 
 25 mM HEPES, pH 7.4 
 25 mM β-glycerophosphate 
 25 mM magnesium chloride 
 0.5 mM dithiothreitol (DTT) 
 0.1 mM sodium orthovanadate  
 
 Make fresh before use and keep on ice.  
 
Kinase assay buffer II (from Haugh Lab) 
 20 mM Tris-HCl, pH 7.5 
 5 mM β-glycerophosphate, pH 7.3 
 1 mM ethylene glycol tetraacetic acid 
 0.2 mM dithiothreitol (DTT) 
 0.1 mg/mL bovine serum albumin 
 15 mM magnesium chloride 
 50 µM ATP  
 
 Make fresh before use and keep on ice. 
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4X SDS-PAGE loading dye 
 2 mL of 1 M Tris-HCl pH 6.8 
 0.8 g of sodium dodecylsulfate 
 4 mL of glycerol 
 400 µL of β-mercaptoethanol 
 8 mg of bromophenol blue 
  
Add water to fill to 10 mL and store at room temperature. 
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